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Abstract
Alzheimer's disease is a progressive incurable neurological disorder and is the leading cause of dementia 
in the elderly. Common symptoms include failure of memory, language and mood disturbances 
confusion and depression. The clinical duration of Alzheimer's disease is approximately 8-10 years post­
diagnosis and patients require increasing assistance throughout its progression. The currently available 
treatments are palliative, focussing on improving cognition and only result in mild improvements in 
small subsets of patients for a relatively short period of time. It is therefore clear that new approaches 
are needed if a therapy is to be developed that has the potential to be disease modifying and slows the 
progression of Alzheimer's disease.
One of the main pathological hallmarks of Alzheimer's disease is the accumulation of beta-amyloid (Ap) 
peptides in the brain. In particular the soluble Ap species has been linked to neurotoxicity, reductions in 
longterm potentiation, and can induce cognitive deficits in animal models of AD after intracerebral 
injection. In addition, increased accumulation of Ap in the brain is also associated with the APOE4 allele, 
which is the strongest genetic factor for developing Alzheimer's disease. APOE exists as three alleles 
with the two copies of the APOE4 allele conferring a 15-fold increase in the risk of developing AD when 
compared to APOE3 homozygous individuals.
Recently it has been demonstrated that this accumulation occurs as a result of defective clearance 
mechanisms. One of the main routes of clearance of A3 is through the blood-brain barrier (BBB) where 
specialised transporters facilitate its clearance. The Low Density Lipoprotein receptor-related protein 
(LRP1) plays a prominent role in the BBB clearance of Ap and its surface expression is at least in part 
regulated by ectodomain cleavage by a variety of 'sheddases'. In particular, this thesis focuses on the 
previously identified LRP1 sheddases ADAM10 and MMP9. The shedding of LRP1 produces a soluble 
LRPl fragment, which is unable to endocytose and subsequently transcytose bound ligands.
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In this thesis, I examined the role of apoE in the regulation of LRP1 and the transcytosis and clearance of 
Ap through the BBB. I demonstrate that the shedding of LRP1 is modulated by the different apoE 
isoforms and that inhibition of LRP1 sheddases increases the clearance of AP through the BBB. MMP9 is 
the primary candidate as the main driver of this mechanism due to its apoE isoform dependent activity 
and increased expression in AD. In summary, I identified a novel target for treatment strategies that 
facilitates the clearance of Ap though the BBB. This approach may be particularly effect in individuals 
with the APOE4 allele, who are in desperate need of viable therapeutics to combat AD.
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Chapter 1 :  Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disease associated with the build-up of 
beta-amyloid proteins (AP) in the brain and cerebrovasculature, in addition to the formation of 
neurofibrillary tangles (NFTs) comprised of a microtubule associated protein tau [1]. The accumulation 
of AP precedes both the neuroinflammatory and neurotoxic events associated with the disease, 
suggesting it may be a driving factor in the development of AD [2]. In addition, levels of soluble 
oligomeric Ap in the brain correlate with the extent of neurodegeneration as well as the severity of the 
cognitive symptoms, indicating its involvement in the chronic deterioration associated with AD [3,4].
The majority of AD cases are sporadic and idiopathic, accounting for approximately 98% of the cases, 
with the remaining 2% occurring as result of autosomal dominant mutations [5]. AD is characterized by 
alterations in higher cognitive functions including: learning and memory, mood, loss of appetite, social 
behaviour, hyperactivity, and depression [6]. Currently, the clinical diagnosis is based on several criteria 
including the Mini-Mental Status Exam (MMSE), neurological, psychiatric examinations, medical history, 
and neuroimaging techniques, the latter of which has only recently become a viable method [7]. Despite 
the recent advances in the field of neuroimaging, especially in early diagnosis at preclinical stages, these 
approaches currently lack specificity and are mostly used in a clinical setting to rule out other similar 
conditions. Therefore, confirmation of AD diagnosis is still only possible with post-mortem pathological 
analyses based on the presence of extracellular AP plaques and Neurofibrillary Tangles (NFTs) which are 
located primarily in the hippocampus, amygdala and cerebral cortex [8,9]. It should also be noted that 
Ap plaques and tau tangles are present in the brains of elderly non-AD individuals, albeit to a much 
lesser degree than in AD subjects [10].
1.1 Prevalence of Alzheimer's disease and current therapies
Worldwide, it was estimated in 2012 that there were over 34 million people currently effected by AD, 
and that the prevalence of the disease will triple by 2050 [11]. In developed countries with aging
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populations, dementias, of which AD is the most common type, are of particular concern. This is due to 
their chronicity, the lack of effective treatments, the high caregiver burden, and the high personal and 
financial cost. Despite a concerted effort by the research community, a cure has yet to be identified and 
only palliative treatments with marginal effectiveness are currently utilised. Of the 413 clinical trials in 
phase I, II or III completed between 2002 and 2012, 99.6% of those failed, leaving only a 0.4% success 
rate [12]. There are currently only 5 medications which are prescribed for the palliative care of AD and 
primarily target cognitive and memory deficits. These include four acetylcholinesterase inhibitors 
(tacrine, rivastigmine, galantamine and donepezil) and one NMDA receptor agonist (memantine) which 
was the only FDA approved drug between 2002 and 2012. However, the improvements which occur as a 
result of these treatments only range from marginal to modest in cognitive assessments, and benefits to 
behavioural symptoms and day-to-day activities have demonstrated mixed results [13,14]. Even when 
administered as a combination therapy, donepezil and memantine only show statistically significant 
improvements in cognition which were considered clinically marginal [15]. The poor efficacy of existing 
treatments suggests a lack of understanding of both the aetiology and the pathological mechanisms 
driving the development of AD. What is clear, is the that therapies targeting the cognitive symptoms 
associated with AD have had limited success and new treatment strategies are necessary, particularly 
those that are disease modifying.
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Figure 1.1 Processing of APP by the a-, P- and y-secretases. Approximately 10% of APP enters the 
amyloidogenic pathway (left) which is driven by p-secretase cleavage of APP and results in the 
eventual production of Ap. This initial step produces a sAPPP protein and a fragment containing the 
remaining 99 amino acids in the APP sequence (C99). This C99 fragment is subsequently cleaved by 
the y-secretase to produce an Ap peptide whose size ranges from 38 to 42 amino acids in length, with 
Ap40 proving to be the most common. The other fragment produced is the AICD which may have a 
role in transcriptional activation, although this role remains controversial. The remaining 90% of the 
APP processing is diverted down the non-amyloidodenic pathway by the a-secretase mediated 
cleavage of APP which occurs in the AP domain, thus preventing the generation of the Ap peptide. 
The two fragments produced by a-secretase cleavage are the larger sAPPa and the smaller carboxy- 
terminal fragment (C83). The C83 fragment can undergo further processing by the y-secretase to 
produce the P3 fragment, which currently has an unknown biological role, and the AICD.
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Over the past decade, one of the major disease modifying approaches investigated for the treatment of 
AD has been to modulate the proteases involved in the production of Ap. AP is produced from the 
amyloid precursor protein (APP), which is primarily expressed on neurons, by the P- and y-secretases 
[16]. After the initial production of APP, it is trafficked to the cellular membrane where it is rapidly re­
internalised and localised to the Golgi apparatus [17]. Here, it undergoes the amyloidogenic processing, 
eventually producing the Ap peptides through the sequential cleavage of APP by the p- and y-secretases. 
This process initially results in a soluble APPP (sAPPP) before further processing by y-secretases which 
produces an APP intracellular domain (AICD) and an Ap peptide (Figure 1.1)[16]. AP is subsequently 
trafficked into endosomes and is then released into the extracellular environment [18]. These Ap 
peptides range in length, from between 32 to 43 amino acids due to the imprecise cleavage in the final 
y-secretase mediated step, with AP40 proving to be the most common form [19]. Of the possible species 
produced, AP42 has the strongest tendency to aggregate and is thought to be the driving factor behind 
the formation of amyloid plaques and the neurotoxic events seen in AD [20].
1.2 The amyloid cascade hypothesis and familial Alzheimer's disease
While the pathophysiology of AD is incredibly diverse, the prevailing hypothesis for the aetiology of AD 
over the last 20 years has been the amyloid cascade . This theory was developed as a result of the 
identification of several mutations in the APP gene that caused overproduction and deposition of AP 
resulting in the formation of AP plaques. These mutations were found to cause the early onset familial 
AD (FAD) and, while cases remain rare in comparison to sporadic AD, they have nevertheless played an 
important role in establishing the central role of Ap in AD, in addition to being vitally important for the 
development of AD animal models. Currently, more than 25 mutations in the APP gene have been 
identified that result in FAD as well as several other related hereditary diseases such as cerebral amyloid 
angiopathy (CAA) (http://www.molgen.ua.ac.be/ADmutations/). In addition to mutations in the APP
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gene, several mutations have been identified in the y-secretase subunits presenilin 1 (PS1) and 
presenilin 2 (PS2), many of which have also been integrated into animal models of AD. While the 
presentation of the pathology that occurs as a result of these mutations varies slightly, as does the level 
of penetrance, all result in the overproduction and deposition of A(3. Interestingly, a mutation in the APP 
gene (A673T) was recently discovered that was found to protect individuals from AD by reducing the 
production of Ap [21,22]. While this mutation remains rare, even compared to other FAD mutations, it 
further confirms the role of AP and its accumulation in the pathology of AD [23].
Even with the advances that the identification of these mutations allowed in the understanding of AD 
aetiology, the amyloid cascade hypothesis required multiple revisions over the years. More recently, it 
has been discovered that the expression of aggregated AP fibrils, which are a major component of the 
AP plaques, does not correlate well with the neuronal apoptosis and synaptic dysfunction seen in AD. 
While the aggregation of AP remains a prominent feature of AD, and is still one of the primary 
conditions required for a positive diagnosis of AD at autopsy [24], the soluble oligomeric species appear 
to be the main driver of Ap-related toxicity [20,25,26]. Oligomeric Ap is found both extra- and intra- 
cellularly and can translocate between the two environments [27,28]. While it is now well established 
that oligomeric Ap accumulation results in a toxic cellular environment, the exact oligomeric structures 
and mechanisms by which Ap toxicity is induced have not been conclusively demonstrated. However, 
the mechanisms that have been identified broadly fit into three categories: receptor-mediated 
neurotoxicity, cellular membrane dysfunction, and intracellular AP toxicity [29]. The receptor-mediated 
toxicity is thought to occur as a result of Ap binding to several different receptor types. These include 
the NMDA receptors, where they interfere with longterm potentiation induction and several 
downstream signalling pathways [30], and the a7 nicotinic acetylcholine receptor (a7nAChR), which has 
been shown to have particularly high affinity with AP and results in the internalisation of the receptor 
and the bound Ap peptide [31,32]. The accumulation of intracellular Ap oligomers has long been linked 
to AD, although the mechanisms by which this may cause neurotoxicity remain unclear. The strongest
evidence for its mechanism of action suggests the intracellular accumulation of AP may inhibit several 
pathways in the ubiquitin-proteasome system and may therefore impair the endocytic trafficking of 
neuronal receptors [33]. In addition to this, accumulation of AP has also been observed in mitochondria 
and was related to diminished enzymatic activity and efficiency [34]. Finally, Ap oligomers are also 
associated with a deterioration in the plasma membrane integrity, which is associated with an increase 
in permeability and elevated intracellular calcium concentration [35,36]. There are several theories as to 
the exact mechanism by which this dysfunction occurs, but most well established theories propose that 
AP induces enhanced ion mobility through lipid bilayers or that cation-specific channels are formed by 
AP oligomers themselves [37-39].
1.3 Blocking production of Ap as a therapeutic approach
As indicated above, inhibition of both the p- and y-secretases with the aim of blocking the production of 
Ap were highlighted as prime targets to reduce the levels of AP that excessively accumulate in the AD 
brain. However, both approaches have met with disappointing results and have either failed to reach 
their clinical endpoint or were stopped due to adverse reactions [40-42]. For example, the phase III 
clinical trial of the y-secretase inhibitor semagecestat was halted after a pre-planned interim analysis 
which identified an increased incidence of skin cancer, gastrointestinal symptoms and worsening 
cognitive scores in the treatment group. While the cause of these side-effects are as of yet unknown, it 
has been suggested that it may be as a result of altered processing of the Notch signalling pathway 
which is required in several cell fate decisions. However, this has yet to be conclusively demonstrated 
and there are several other proteins that are associated with y-secretase function that could result in 
some of the observed off-target effects [43-45]. Similarly, targeting the P-secretases via small molecule 
inhibitors has also proved challenging. This is thought to be at least in part due to the relatively large 
catalytic site responsible for the p-cleavage of APP. In vitro, inhibition of p-secretases can easily be
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achieved with larger inhibitor molecules. Unfortunately, these inhibitors have not successfully translated 
into in vivo paradigms due to difficulties arising from bioavailability and penetration of the blood-brain 
barrier (BBB) [46], In addition, off-target effects have often been reported with 3-secretase inhibitors 
[47,48]. For example, the p-secretase inhibitor RG7129 was withdrawn from development after a phase 
I trial in 2013, most probably as a result of high levels of liver toxicity, although an official report was 
never released [48]. However, despite these failures, there are several p-secretase inhibitors still under 
investigation, although the attrition rate for the potential treatments remains high [40].
1.4 Antibody based therapeutic approaches
Another avenue of therapeutic intervention in AD has been through the use of Ap directed 
immunotherapy. Similar to the targeting of the p- and y-secretases, both active immunisation (injection 
of a non-toxic, non-fibrillogenic modified AP peptide) and passive immunisation (injection of 'pre-made' 
monoclonal anti-AP antibodies) were designed to reduce the levels of Ap in the brain, albeit through 
difference mechanisms. For example, active immunisation aims to stimulate production of anti-Ap 
antibodies in the periphery, acting as a peripheral sink for Ap, whereas passive immunisation aims to 
increase clearance of Ap by binding to AP in the brain and inducing Fc-mediated phagocytosis by 
microglia [49,50]. Initially, both active and passive immunisation approaches produced promising results 
in animal models [49,51]. However, clinical trials using the active immunisation approaches have shown 
little of no benefit [52,53]. In addition active immunisation was found to induce considerable side effects 
including the development of meningoencephalitis [52]. However, several of the current generation of 
active immunisation approaches have showed positive results in phase I trials, although none have yet 
published a successful outcome in phase II [54]. In comparison to the active immunisation route, passive 
immunisation remains a more active area of research, although the first generation passive 
immunisation antibodies also displayed little or no benefit to patients [55,56]. To date, multiple phase II
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and III trials have been completed to varying degrees of success using passive immunisation. These 
include the phase III clinical trial utilising solanezumab, a humanised murine antibody directed against 
soluble Ap species, which showed some significant improvements. However, this positive outcome was 
only evident in the neuropsychological tests of the patients with the mildest disease, suggesting that 
intervention in the early stages, or even prophylactic therapy may be beneficial [57]. Despite the more 
positive results from such trials, the passive immunisation approaches are also not without considerable 
side effects, with a number of patients developing what became known as amyloid-related imaging 
abnormalities (ARIA). These are comprised of two subsets and were originally detected through 
magnetic resonance imaging (MRI): ARIA-E, which is thought to represent vasogenic oedema and 
breakdown of the BBB, and ARIA-H which represents microhaemorrhages in the cerebrovasculature 
[58]. These side effects were found to be relatively common in some passive immunisation approaches, 
with all phases of the trials utilising the humanised monoclonal anti-Ap antibody bapineuzumab 
observing increased ARIA associated with increasing dose of treatment [55,59,60]. In response to this, 
MRI imaging techniques are now widely used to assess safety outcomes in clinical trials and to screen for 
ARIA side effects [61]. Perhaps the most promising passive immunotherapy currently undergoing clinical 
trials is the human monoclonal antibody, Aducanumab, which has demonstrated dose dependent 
reductions in amyloid deposition and slow in the decline of the MMSE scores [62]. Similarly to other 
passive immunisation approaches, ARIAs have been observed with Aducanumab treatment, especially in 
the higher doses and in the APOE4 genotype [62]. However, the indications from the Aducanumab trails 
remain positive and a large scale phase 3 trial is expected to conclude in 2022 (ClinicalTrials.gov 
identifier: NCT02477800).
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1.5 Stimulating non-amyloidogenic processes as a therapeutic approach
In addition to the amyloidogenic processing of APP, it is also proteolytically shed by the a-secretase 
family of proteins resulting in a sAPPa fragment. There have been several proteases identified that are 
capable of facilitating cleavage of APP at the a-site, although in neurons it is likely that A disintegrin and 
metalloproteinase 10 (ADAM10) is the main constitutively active protease [63,64]. The benefits of 
processing APP through the a-secretases route are two-fold. Firstly, sAPPa peptides have been 
demonstrated to have both neuroprotective and proliferative functions such as supporting the 
proliferation of neural stem cells [65]. In addition, the cleavage site for the a-secretases is located in the 
Ap domain of APP, essentially blocking the ability of (3-secretases to initiate the amyloidogenic cascade 
of APP, thus precluding the production of A(3. Strategies targeting the a-secretase pathway, with the aim 
of modulating the production of APP, have been slower to progress, possibly due to the research 
communities focus on the inhibition of 0- and y-secretases as well as the immunotherapy approaches. 
Despite this, animal models and in vitro studies utilising an a-secretase activator, bryostatin, have shown 
promising results and good tolerability in phase I trials [66,67]. As a result, one phase 2 trial using 
bryostatin, initiated in 2015, is currently undergoing recruitment for moderate to severe AD 
(ClinicalTrials.gov identifier: NCT02431468). Aside from large scale clinical trials, there are early 
indications that bryostatin may show efficacy due to results from a compassionate use trial in a single 
patient with a PS1 mutation resulting in very early onset dementia and expressive aphasia [68]. This 
patient demonstrated improvements in speech, increased attention focus and improved ability to 
swallow as well as a decrease in limb spasticity with treatment.
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1.6 The use of genome wide association studies to identify new targets
In contrast to these targeted lines of investigation, some research teams are taking a more global 
approach to understanding the mechanisms that are contributing to AD. Within the last five years, the 
largest genome wide association study investigating the genetic underpinnings of the progressive 
cognitive decline witnessed in sporadic AD was completed [69]. This study, which had over 74 000 
participants, identified 19 gene loci, 11 of which were newly associated with AD, in addition to the APOE 
locus. Of these loci, immune-inflammatory genes were overrepresented suggesting that modulation of 
the brain's resident immune system is also implicated in the pathology, of AD. This study was initiated, at 
least in part, due to the discovery of a rare susceptibility variant of the TREM2 gene which was found 
more frequently in AD patients [70]. TREM2 encodes the triggering receptor on myeloid cells 2 protein, 
which together with the TYRO protein tyrosine kinase-binding protein (TYROBP) triggers activation of 
the immune response in macrophages and dendritic cells [71]. The Trem2 protein is involved in the 
phagocytic pathway in microglia which is thought to be protective and result in the removal of cellular 
debris in the CNS and clearance of A(3 peptides in AD. In support of this, detection of activated microglia 
is well established as a marker for AD pathology in animal models. However, it remains unclear if this 
activation of microglia is a driver of pathology or simply a reaction to the inflammatory environment. 
There is some evidence to suggest that the activity of microglia, while initially anti-inflammatory may 
switch to a pro-inflammatory state after chronic exposure to A3 peptides, resulting in reduced uptake of 
A3 and increased production of pro-inflammatory cytokines and reactive oxygen species [72-74].
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1.7 Mechanisms for the elimination of Ap from the brain
Despite a concerted effort by both the research community and pharmaceutical companies to address 
the unmet need for treatments of AD, none of the current therapeutic avenues have, as of yet, reached 
an acceptable clinical outcome. Therefore, it is important to consider other strategies targeting 
alternative mechanisms that may be leveraged to modify AD progression. Recent research has 
suggested that the accumulation of A3 may be due to a dysfunction of the A3 clearance mechanism in 
the brain, and not through elevated or excessive production of A3 [75]. Several mechanisms have been 
identified that contribute to the removal of A3 from the brain which broadly fit into three distinct 
categories: enzymatic degradation, fluid/bulk flow clearance, and clearance through the BBB.
1.7.1 Enzymatic degradation
Enzymatic degradation of A3 occurs both intra- and extra-cellularly by a diverse array of proteases. The 
extracellular degradation of peptides in the ISF is mainly attributed to the enzymatic activity of 
proteases secreted by astrocytes whereas the intracellular degradation occurs after internalisation of 
proteins into microglia and astrocytes. Once internalised, degradation occurs in several cellular 
compartments such as the endosomal and lysosomal compartments [76]. Of the proteases involved, 
neprilysin (NEP) and insulin-degrading enzyme (IDE) are perhaps the best characterised and have been 
found to show reduced expression in the hippocampus with age [77-79]. In addition NEP protein levels, 
mRNA and activity were all found to be reduced in AD when compared to normal controls [80]. The 
involvement of NEP in AD has been further studied in animal models of AD, with mice over-expressing 
NEP in neurons showing significantly lower levels of A3 in the brain and no formation of A3 plaques 
when compared to controls [81]. Interestingly, increasing expression of NEP in the periphery also 
appears to reduce the levels of A3 in the brain [82]. However, modulation of NEP activity or expression 
may impact multiple cellular processes, particularly those involved in the regulation of the
cardiovascular system [83]. Moreover, high levels of NEP have been linked to congestive heart failure 
[84]. As a result, there is currently a phase III clinical trial investigating the viability of the NEP inhibitor, 
LCZ696, as a treatment for congestive heart failure (ClinicalTrials.gov identifier: NCT01920711). This 
suggests treatments that would result in a systemic increase in the expression of NEP, with the aim of 
facilitating the clearance of A3 from the brain in AD may be not be a viable strategy as a result of the 
potential side-effects in the cardiovascular system. Regardless, this remains an area of active research 
and modulating cell specific expression of NEP remains a viable therapeutic target for increasing A3 
degradation [85].
1.7.2 Bulk flow clearance from the brain
Broadly speaking, there are two main fluid based clearance mechanisms in the brain, consisting of peri- 
and paravascular clearance pathways, both of which are capable of removing A3 from the brain. The 
perivascular drainage pathway relies on perivascular arterial spaces which is are CSF-filled cavities that 
surround the small penetrating cerebral arterioles. These anatomical structures collapse on cardiac 
arrest and perivascular drainage stops, suggesting that vascular pulsations may be the motive force for 
this mechanism of clearance [85-87]. Studies have demonstrated that tracers injected into murine 
brains were found to rapidly colocalise with the vascular basement membranes in capillaries and 
arteries where they then flow in a opposite direction to the blood flow towards the subarachnoid space 
[86,88]. Solutes, such as A3, are then ultimately cleared from the brain via the cervical lymph nodes [89]. 
In CAA, is several structural changes in the vasculature, including loss of the smooth muscle around 
arterioles, thickening of the basement membrane and deposition of A3 in the parenchyma are observed 
[90-92]. It occurs in a significant portion of the elderly population and in over 80% of AD patients 
[93,94]. The presence of CAA in animal models of AD was found to result in reduced perivascular 
drainage which has been hypothesised to result in a feed-forward process whereby A3 deposition 
promotes further A3 deposition in the vasculature, further dampening the perivascular drainage of 
solutes [95]. However, the perivascular clearance of A3 is believed to be approximately 6-fold slower
than the transport into the blood via the BBB, suggesting that dysfunction in this clearance pathway may 
not be as impactful [96]. Regardless, chronic reductions in the perivascular drainage of A3 from the 
brain are probably still a contributing factor to the reduced total clearance of A3 witnessed in AD.
In contrast to perivascular drainage, paravascular (or glymphatic) clearance relies on the convective bulk 
flow of ISF away from arterioles to veins. This has been shown to be driven, at least in part, in part by 
the aquaporin 4 (AQP4) water channels expressed in astrocytic end feet, with AQP4 KO mice showing 
approximately 70% reduction in removal of solutes from the brain [97]. The first stage of paravascular 
clearance requires CSF influx into the periarterial space which occurs in the same direction as blood 
flow. Here the water from CSF drains through the AQP4 channels and enters into the brain parenchyma 
before the pressure gradient allows exit of fluid from the brain via AQP4 channels at the venous side. 
Waste then recirculates into the CSF or is cleared via the lymphatic systems [98]. With regards to AD, it 
was demonstrated that mice lacking astrocytic AQP4 had significantly reduced clearance of A3 from the 
brain [97]. In addition, paravascular drainage and AQP4 expression it has also been shown to be change 
with age, indicating it may be a contributing factor for the risk of developing AD [99]. However, while it 
has been reported that disruption of paravascular drainage reduced A3 clearance by approximately 55%, 
it was also shown that A3 was cleared from the brain at a significantly faster rate than a comparable 
sized dextran [97]. This suggests that there is a selective clearance mechanism in the brain that 
specifically targets A3 over molecules of the same size.In support of this, it has previously been shown 
the A3 is cleared from the brain at rates far higher than can be attributed so bulk flow mechanisms, 
indicating other mechanisms, such as active or receptor mediated clearance at the BBB, may be a more 
prominent clearance route [100].
1.7.4 Clearance of Ap through the BBB and LRP1
One of the main routes of A3 elimination from the brain is through the BBB, accounting for at least 25% 
of total A3 clearance [100,101], The reduced BBB clearance and accumulation of A3 in the AD brain is, at
least in part, believed to occur as a result of disrupted Ap transporter function in brain capillaries 
[100,102,103]. Findings such as these has led to the development of the neurovascular hypothesis of AD 
which has been steadily gaining support over the past decade [102,100,96]. The BBB is formed primarily 
by endothelial cells and pericytes, although it requires additional support from astrocytes and neurons 
to maintain its integrity and function. Collectively, these components are termed the neurovascular unit. 
The cross talk between different cells of the neurovascular unit helps regulate the permeability of the 
BBB as well as cerebral blood flow (Figure 1.2). In particular, pericytes appear to have a prominent role 
in maintaining BBB integrity, with reductions in cell number and the subsequent breakdown of the BBB 
strongly associated with the development of AD pathology [104]. In comparison to peripheral blood 
vessels, movement of molecules through the BBB is tightly regulated. Charged molecules and larger 
proteins such as Ap generally have very poor permeability across the BBB, and require specific 
transporter mechanisms to allow movement in either direction.
While pericytes are involved in the regulation of the BBB, the actual paracellular barrier is formed by 
endothelial cells as a result of the presence tight junction proteins. The tight junction proteins consist of 
at least 40 different proteins and are located at the cell-cell interfaces [105,106]. The primary tight 
junction proteins are the occludin and the claudin proteins which are found at the interface proximal to 
the lumen of vessels. The claudins are a family of over 20 proteins form tight junction barriers through a 
claudin-claudin interaction. At the BBB, claudin-1, -5, -3 and -12 are expressed to varying degrees, with 
claudin-5 being the most prevalent [107,108]. A reduction in claudin-5 expression is associated with 
ischemic insult and exposure to Ap peptides, with complete knockout of caludin-5 resulting in severe 
BBB disruption and changes in BBB permeability [109-111]. In comparison to the claudins, the role of 
occludin proteins in the formation of the BBB is not as clearly established. On one hand, studies have 
linked the expression of occludin with control of membrane integrity as measured by electrical 
resistance [112]. In addition, occludin degradation induced by viral or bacterial infection increases the 
permeability of in vitro BBB models [113,114]. However, occludin deficient mice display normal tight
junction functionality suggesting that expression of occludin may not be essential for the formation of 
the BBB changes, and that BBB function is not dependent on the occludin proteins [115,116].
The main adaptor proteins responsible for the anchoring both claudin and occludin to the cytoskeleton 
in endothelial cells are the zonula occludens (ZO)-l, -2 and -3 proteins which have been shown to be 
essential for the assembly of tight junction proteins [117,118]. ZO-1 in particular appears to be 
important, with ZO-1 KO mutations proving to be embryonically lethal as it is required for normal blood 
vessel formation in the yolk sac. This suggests that it may be an indispensible protein for the 
organisation of the endothelial tissue [119]. Furthermore evidence for the essential role of ZO-1 in 
barrier function was found in vitro, with KO of ZO-1 proving to be much more disruptive to barrier 
formation and function than depletion of any other tight junction proteins [120].
As a result of this tight junction barrier, larger molecules that are not readily permeable through the 
BBB, such as Ap peptides, require specific transporters to facilitate clearance from the brain. There are 
several receptors that are capable of facilitating the transport of Ap through the BBB. These include P- 
glycoprotein (Pgp) and class members of the low density lipoprotein receptor (LDL) receptors 
[121,121,122]. Although the relative importance of these receptors in the clearance of AP through the 
BBB is disputed, a recent study using endothelial specific KO mice identified that the LDL receptor, low 
density lipoprotein receptor-related protein 1 (LRP1) was responsible for approximately 50% of the total 
BBB clearance of Ap42, suggesting that this may be the primary receptor responsible for the clearance 
of AP from the brain [123]. It should also be noted that while both LRP1 and Pgp expression has been 
found to be reduce with age, loss in LRP1 expression occurs at a much younger age. This suggest that 
LRP1 may the original driver for the reduced clearance of AP and its subsequent accumulation witnessed 
in AD, whereas reductions in Pgp expression may be a secondary pathology [124].
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1.8 LRP1 mediated clearance of Ap through the BBB
LRPl is expressed on a variety of different cell types in the CNS, in addition to the endothelial cells, 
where it is responsible for the uptake of Ap from the extracellular matrix for proteolytic degradation 
[125-128]. When expressed on the endothelial cells of the BBB, binding of Ap to LRPl at the abluminal 
(brain-side) of the BBB causes rapid clearance of Ap through transcytosis across the BBB into the blood 
[100,129,130]. This rapid transcytosis has been demonstrated in vivo, where the rate in which Ap was 
cleared through the BBB was found to be far higher than the rate in which it is transported by bulk flow, 
implicating receptor mediated transport as a major mechanism for eliminating AP through the BBB [96]. 
While LRPl is not the only member of the LDL receptor family that is capable of binding AP and 
facilitating transcytosis, it is thought to be the main receptor responsible for the endocytosis of ligands 
due to its faster rate of internalisation. For example, the very low density lipoprotein receptor (VLDLR) 
and LRP8 receptors from the LDL family internalise ligands at a t i /2 of roughly 8mins, whereas LRPl has a 
t i /2 of 0.5mins [131]. After the rapid internalisation of the LRPl and ligand complex, the ligands are 
dissociated from LRPl in the early endosomes and the receptor is subsequently recycled back to the cell 
surface [132]. The definitive evidence for the importance of LRPl in the transport of AP across the BBB 
was recently obtained by a group led by Storck et al. who developed conditional endothelial LRPl KO 
mice in a FAD mouse model. These mice displayed a accelerated AD phenotype compared to FAD mice 
expressing endothelial LRPl, with significant reductions in Ap-BBB transit, increased soluble AP in the 
brain, and deficits in memory and spatial learning [123]. This study demonstrates that reduced BBB 
clearance of AP is sufficient to exacerbate an AD phenotype in an AD mouse model. In addition, it 
confirms the vital role which LRPl plays in clearance of AP through the BBB and the consequences that 
arise when this process is disrupted [123]. However, it remains unclear whether the loss of LRPl
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expression in isolation is sufficient to induce an AD phenotype in humans without the increased 
production of Ap found in animal models of AD.
LRPl is produced as a precursor protein which is cleaved into two subunits in the Golgi complex by furin­
like endoproteases resulting in a 515kDa a- and a 85kDa P-chain [133]. After this proteolytic processing, 
the extracellular domain 515kDa fragment is non-covalently bound to the transmembrane 85kDa 
domain of LRPl and is trafficked to the cell surface [134,135]. Interestingly, aside from the endothelial 
cells, LRPl is also highly expressed in several cell types in the CNS where it is involved in cholesterol 
regulation of uptake of Ap. These include the microglia and neurons where LRPl plays a major role in 
the uptake of Ap for subsequent degradation [126,136]. LRPl expression is also particularly high in the 
liver where it is involved in the final hepatic clearance of Ap out of the body [137]. Interestingly, LRPl 
expression has been found to decrease with age and in AD, likely resulting in reduced clearance of Ap 
from the brain and implicating altered LRPl expression as an early AD pathology and even potentially an 
aetiology of the disease [124,138].
The surface expression of LRPl and its ability to facilitate clearance of AP through the BBB is at least in 
part regulated by the ectodomain shedding of LRPl by proteases at the cell surface. This results in the 
formation of a soluble 515Da fragment that loses the ability to transcytose Ap but maintains its binding 
profile. As a result, soluble LRPl is detected in senile plaques co-localised with Ap [140]. This preserved 
binding profile of soluble LRPl has also been recognised for its potential as a AD therapeutic, with 
administration of soluble LRPl fragments in the periphery acting as a peripheral sink for AP, promoting 
the continuous removal of AP from the brain [130]. Under normal conditions, this circulating soluble 
LRPl is believed to sequester approximately 70-90% of free AP while also facilitating its eventual 
removal from the plasma [130]. In AD patients, this peripheral soluble LRPl appears to have reduced 
ability to bind AP peptides, potentially as a result of increased oxidation, and therefore is unable to 
prevent re-entry of AP to the brain through transport by the receptor for advance glycation end
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products (RAGE)[141,142J. There is some evidence to suggest tha t the balance between the LRPl 
mediated efflux o f A(3 and A(3 influx as a result o f RAGE may be altered in AD. For instance, under normal 
conditions, the expression o f LRPl appears to  be prim arily in the vasculature while RAGE is expressed at
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Figure 1.2 Organisation of the neurovascular unit. The structure and composition of the 
cerebrovasculature changes depending on the location. (A) The intracerebral arteries contain rings of 
vascular smooth muscle cells (blue) which encircle the endothelial cells and occupy most of the 
vascular wall. (B) After branching, brain capillaries are formed that lack the smooth muscle and are 
wrapped in pericytes (green). These pericytes envelop the branching capillaries and share a basement 
membrane with the endothelial cells (pink). The pericytes play multiple roles in the function and 
integrity of the neurovascular unit including the regulation of blood flow, secretion of extracellular 
matrix proteins and contribute to the clearance of cellular debris. Astrocytic end feet (yellow) help 
maintain a cellular link to the neurons (purple) in addition to maintaining BBB integrity, recycling 
glutamate to glutamine for neurons and maintaining homeostatic conditions in the brain. Image 
adapted with permission from Hamilton et al.[139].
a high density in the neurons [143]. However, in AD, the expression patterns are inverted, with LRPl 
primarily expression in neurons and robust RAGE expression in the vasculature [143]. RAGE directed 
therapies have also shown some promise in ameliorating AD like pathologies and symptoms with anti- 
RAGE IgG increasing cerebral blood flow. In addition, mice overexpressing neuronal RAGE, which as 
previously discussed, is high in non-AD neurons, improved performances in special learning and memory 
tests. Despite these promising preclinical results and good tolerability of the RAGE inhibitor PF- 
004494700 in a phase I trial [144], the phase II trial was halted after interim analysis showed no benefit 
and treatment along with all future studies were abandoned [145]. Therefore, in the wake of these 
disappointing results, blocking LRPl 'sheddases', and therefore the inactivation of LRPl through 
ectodomain shedding, remains an attractive avenue for therapeutic intervention. Some of the most 
prominent sheddases implicated in the ectodomain shedding of LRPl include the a-secretase ADAM10 
[146] and the matrix metalloproteinase 9 (MMP9) [147]. However, their physiological role in the 
shedding of LRPl and AD pathology has yet to be conclusively studied.
1.9 Non-Ap clearance roles of LRPl
Aside from the clearance of Ap in the BBB, LRPl is also involved in many other homeostatic and 
signalling processes in the brain. For instance, in forebrain specific knockout of LRPl in mice display 
reduced dendritic spine densities and synaptic impairments, neurodegeneration in the absence of 
amyloid pathology, neuroinflammation and behavioural alterations [148]. LRPl also plays a prominent 
role in cholesterol and apoE metabolism in neurons, with altered lipid and cholesterol uptake associated 
with exacerbated A3 pathology in mice overexpressing APP in conjunction to a conditional KO of LRPl in 
the forebrain [149].
In addition to its lipid metabolism and endocytic activity, LRPl is also involved in the regulation of
signalling pathways in response to ligand binding [150]. For example, the binding of tPA to LRPl induces
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Src family kinase activation and signalling through Trk receptors [151]. Reductions in Trk signalling have 
previously been detected in mouse models of AD where they were linked with deficits in memory based 
tasks [152]. In addition, altered Trk receptor expression has been found in neurons of AD patients 
suggesting that regulation of signalling through LRPl may also be altered in AD [153]. The intracellular 
domain of LRPl (ICD) has also been demonstrated to be involved in several signalling cascades and in 
the regulation of transcription, which requires prior proteolytic cleavage by the y-secretase and 
translocation to the nucleus. For example, the LRPl ICD has been shown to suppress the action of the 
interferon-y promoter, resulting in the suppression of inflammatory responses [154,155]. In addition, 
the LRPl ICD may have a role in the regulation of APP, as the LRP-ICD has been found to be highly 
colocalised with the APP transcriptional regulator, Tip60, in the nucleus [156], It has therefore been 
suggested that basal levels of LRPl shedding may be an important mechanism in the regulation of 
protein expression or cell signalling. However, it should also be noted that much of this work remains a 
speculative, and more information is required to conclusively prove that LRPl shedding is directly 
involved in these events [157].
There is also an immerging role for LRPl in the regulation of normal NMDA receptors function, with 
reductions in NMDA-dependent gene transcription and internalisation of AMPA subunits observed in 
LRPl KO neurons in vitro [158], LRPl is also involved in the expression of the NMDA receptor subunit, 
NR2B, with mice expressing LRPl containing a knock-in mutation in the NPxY domain required for the 
internalisation of the receptor, showing a reduction in NR2B levels. These changes in the NMDA 
receptor subunit composition is at least in part believed to be the cause of the altered behaviour and 
changes in spatial learning observed in LRPl KO models. Finally, LRPl deficiency has also been 
associated with altered vascular function and smooth muscle apoptosis via PDGF receptor mediated 
down-regulation of Bcl-2, further implicating it in the vascular pathogenesis of AD [159].
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1.10 ApoE and Alzheimer's disease
While the genome wide studies in AD identified several risk genes associated with inflammation, the 
main genetic risk factor for AD is the presence of the APOE4 allele [160,161]. ApoE protein exists as a 
34kDa glycoprotein which has three isoform variants in humans (apoE2, apoE3 and apoE4). Possession 
of one or two APOE4 alleles increases the chance of developing AD by 4- and 15- fold respectively when 
compared to APOE3 homozygous individuals [162], In addition, AD patients and transgenic AD animals 
homozygous for APOE3 show reduced brain AP deposition compared to subjects homozygous for APOE4 
[163,164]. As well as having an increased Ap brain load, carriers of the APOE4 allele exhibit brain 
amyloid pathology as early as age 40, experience faster cognitive decline and have an earlier age of 
onset for AD [165,166]. Therefore, the APOE allele is clearly an important factor to consider when 
determining the driving pathologies of AD.
It has also been demonstrated that the apoE isoforms have differing affinities for AP, with apoE3 
showing roughly a 20-fold increase in its association with Ap as compared to apoE4 [167]. The ability of 
apoE to bind receptors and ligands appears to be dependent on its lipidation status, with poorly 
lipidated apoE demonstrating altered binding affinities to Ap. This altered lipidation was associated with 
increased amyloidogenesis in mouse models of AD, suggesting that the lipidation status of apoE may 
play a role in AP pathology [168-170]. There are also some indications that the lipidation status is 
isoform specific and may therefore play a role in causing the isoform specific effects with regards to AD 
pathology and Ap accumulation [171]. However, to our knowledge, no study has yet been carried out 
that assesses the impact of AD on the lipidation status of apoE (in either humans or animal models). As 
such the role of apoE lipidation has yet to be conclusively established. Interestingly, deletion or 
overexpression of the ATP binding cassette A1 (ABCA1), which is responsible for the expression and 
lipidation of astrocyte-derived apoE, results in increased or reduced deposition of Ap respectively in AD 
mouse models [168,169,172]. Another matter to consider is the fact that early studies looking into apoE-
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AP interactions utilised purified apoE that is in a non-lipidated and non-physiological form. These studies 
found inverse binding profiles to those published in later investigations that used apoE in its lipidated 
form [167,173]. Although this requires investigators to use a degree of caution when drawing 
conclusions from older references with an apoE component, it does indicate that the lipidation status of 
apoE may be an important factor to consider when trying to model AD.
1.11 ApoE and LRPl interactions
One of the most closely associated molecules for the LRPl receptor is the apoE protein. Interactions 
between LRPl and apoE have been shown to been involved in complex array of processes including the 
regulation of AP, transcytosis of proteins, and the regulation cholesterol transport in neurons [174].
LRPl and apoE also have several interactions that have been shown to be beneficial for the maintenance 
of vascular function. For instance, in lipoprotein metabolism, the interaction between LRPl and apoE 
stimulates a signalling pathway that results in the initiation of several mechanisms that are protective 
against vascular disease [175]. In addition, LRPl also plays a role in the regulation of apoE recycling. In 
human hepatoma cells, LRPl facilitates the accumulation of apoE in early endosomal and recycling 
compartments, resulting in increased recycling and reduced degradation of apoE [176]. With regards to 
the transcytosis of Ap, the apoE-LRPl interactions appear to influence the rate at which AP is cleared 
from the brain to the periphery in an isoform specific manner [177]. However, it is unclear whether the 
presence of apoE is facilitative or inhibitory as several groups have identified conflicting results 
[96,100,178]. In these studies, it should be noted that experimental conditions which favour the most 
physiological expression of apoE, such as appropriate concentrations and a physiological lipidation 
status, appear to show that apoE has a facilitative influence on the clearance of Ap through the BBB. 
Regardless of whether apoE acts in an inhibitory or facilitative manner when observing AP-BBB 
clearance, the reports are consistent in the fact that apoE4 isoforms always result in the lower levels of
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Ap cleared from the brain compared to the other two isoforms. Our previous studies suggest that apoE 
can have both facilitative and inhibitory effects in terms of clearance of AP through the BBB [179]. These 
studies identified that, when in complex with apoE, AP clearance is significantly reduced. This is in 
comparison to unbound apoE which appears to facilitate the clearance of Ap through the BBB in an 
isoform specific manner [179]. In addition, evidence from autopsied brains appears to support the 
hypothesis that apoE is protective with regards to AD pathology. In this study, analyses of apoE 
expression in over 100 autopsied brains identified an inverse correlation between the apoE levels and 
brain AP load [180]. On this evidence, several therapies directed at increasing the expression of apoE 
were developed, such as the RXR agonist bexarotene and the LXR agonist T090137. Both of these 
compounds have shown some success in animal models of AD, demonstrating the ability to increase the 
clearance of Ap and improve performance memory related tasks [181-184]. However, contradicting 
results have been documented [185] and there are indications that this approach may have limited 
translational application due to systemic hepatomegaly as a result of treatment [186].
1.12 Aims
With the high rate of failure in AD clinical trials over the last decade, expanding the current mechanistic 
understanding of the underlying pathology of AD may not only unveil potential oversights that resulted 
in some of the recent disappointing clinical trials, but also identify potential new therapeutic avenues for 
the treatment of AD. As such, targeting the mechanisms involved in the regulation of LRPl and its ability 
to remove Ap from the brain has, as of yet, not been fully investigated. In addition, despite the strong 
association of the apoE4 isoform with the increased risk of developing AD, the mechanism by which it 
alters LRPl function and its endocytic activity has not been conclusively demonstrated. Therefore, to 
address this, this thesis will investigate the role of LRPl regulation in AD as well as the impact of apoE on 
the functions of LRPl. This will be investigated in the following aims:
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1.To determine the impact of apoE on LRPl shedding and the implications for Ap BBB clearance
• Investigate the impact of Ap on the shedding of LRPl
• Assess the influence of the apoE on the shedding of LRPl and clearance of AP through the BBB
• Determine whether there is an apoE-isoform or AD dependent expression profile for LRPl in the 
brain and cerebrovasculature
• Confirm the proteolytic activity of several of the known sheddases against LRPl
2. Assess the influence of apoE on the internalisation and sub-cellular trafficking of LRPl and Ap in brain 
endothelial cells
• Determine the impact of the apoE isoforms on the internalisation of LRPl and AP
• Evaluate the impact of apoE on the localisation of Ap in early and recycling endosomes
3. Investigate the impact of the LRPl protease ADAM10 on the shedding of LRPl and the implications on 
the clearance of Ap through the BBB
• Analyse the impact of pharmacological inhibition of ADAM10 on the shedding of LRPl and the 
clearance of AP through the BBB in vitro
• Assess the effect of ADAM10 on the clearance of AP through the BBB in vivo with ADAM10 
endothelial specific knock-out mice
• Investigate the impact of ADAM10 inhibition on the shedding of LRPl, clearance of AP through 
the BBB, and the brain AP load in a mouse model of AD
• Evaluate the impact of the apoE isoforms on the activity of ADAM10 in vitro
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4. Determine the influence of apoE on MMP9 and the shedding of LRPl and clearance of Ap through the 
BBB
• Analyse the impact of pharmacological inhibition of MMP9 on the shedding of LRPl and the 
clearance of AP through the BBB in vitro
• Investigate the impact of the apoE isoforms on the activity of MMP9
• Assess the impact of MMP9 and shedding of LRPl in the vasculature of APOE targeted 
replacement mice
• Evaluate the impact of pharmacological inhibition of MMP9 on the shedding of LRPl and the 
clearance of AP through the BBB in APOE targeted replacement mice
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Chapter 2 : ApoE dependent shedding of LR Pl and clearance of A(5 across 
the BBB
2.1 Introduction
The main avenue of exchange between the brain and the periphery for A3 is the Blood Brain Barrier 
(BBB). In comparison to peripheral blood vessels, the movement of molecules through the BBB is tightly 
regulated. Polar molecules, amino acids and molecules larger than 400Da have very poor or no 
permeability across the BBB and require specialised transporters to facilitate transit [187]. One of the 
transport systems located in the BBB is the low density lipoprotein receptor-related protein 1 (LRPl), 
which is a member of the low density lipoprotein (LDL) receptor family. It is one of the receptors 
primarily responsible for the transport of A3 across the BBB [123,125]. This receptor also has numerous 
functions including roles in the regulation of cholesterol transport, cell survival, blood coagulation, and 
synaptic transmission [128,188]. Binding of A3 to LRPl at the abluminal side of the BBB results in rapid 
transcytosis of A3 across the BBB [100,129,130]. In addition, LRPl-mediated transport has also been 
shown to be an important route of elimination from the periphery via hepatic clearance of A3 [137].
Previous studies have demonstrated that LRPl expression is significantly reduced in the vasculature with 
age and in AD [138,189]. A diverse array of ligands have been found to interact with LRPl, including 
apoE [190], a2-macroglobulin (a2M) [151] and APP [191], all of which have been shown to be involved in 
the regulation of A3- In addition, A3 is also well known to bind to the LRPl receptor [192]. Restoring the 
expression of LRPl to facilitate A3 BBB clearance in the neurovasculature has been proposed as a 
potential therapeutic target for the treatment of AD. One promising avenue of study involves the use of 
thiazolidinediones (TZD) such as rosiglitazone or pioglitazone which have previously been shown to 
increase the expression of LRPl. TZDs function through activation of peroxisome proliferator-activated 
receptor-y (PPARy), which has long been in use for treatment of diabetes. Following studies 
demonstrating the epidemiological association between diabetes and AD [193], various TZDs were
investigated as potential AD therapies. Although any beneficial effect of rosiglitazone in AD was initially 
hypothesized to be due to its anti-inflammatory properties [194], it was later found that it may be due 
to up-regulation of LRPl at the BBB. This effect has been demonstrated in several different cell types 
including adipocytes, hepatocytes, liposarcoma (SW872) as well as in human brain microvascular 
endothelial cells (HBMECs)[195-197]. In an AD-focused study, Moon et al. demonstrated that 
treatment of HBMECs with low dose rosiglitazone increased both the expression of LRPl and the cellular 
uptake of Ap [197]. However, they also demonstrated that high dose rosiglitazone did not show the 
same efficacy as the low doses, resulting in reduced expression of LRPl and lowered uptake of Ap. As 
such, simply altering the expression of LRP appears to be mechanistically complex, and may therefore 
not be the most viable approach increase Ap clearance from the brain.
Cell surface expression and function of LRPl is regulated, at least in part, by proteolytic shedding. This 
process yields a soluble LRPl heavy chain fragment of 515kDa which includes the ligand binding sites, 
and an 85kDa light chain membrane bound fragment containing serine and tyrosine phosphorylation 
sites (Figure 2.1) [135,157,198]. Signalling through the serine and tyrosine induces several cellular 
processes including internalization of LRPl, cell division, survival and development[199,200]. Once LRPl 
is cleaved, it loses the capacity to transcytose A3 and may therefore cause reduced clearance of A3 
through the BBB. As demonstrated by Lui et al. and others, shedding of LRPl can be induced by 
exposure to Ap [201,202]. Although inactivated as a transcytosing protein when shed, soluble LRPl 
maintains its high binding capacity and is thought to have several functions including activation of 
macrophages and acting as an amyloid sink in the periphery, the latter of which has been suggested as a 
potential target to reduce brain Ap burden [130]. There are several species that have been identified as 
potential LRPl 'sheddases' including ADAM10 [146], tissue-type plasminogen activator (tPA)[203], and 
matrix metalloproteinase 9 (MMP9) [147]. However, their physiological role in the shedding of LRPl and 
AD pathology has not been conclusively studied.
Page | 44
600kDa
AP AP
Cluster
I
I I  ApoE, a 2M , tPA 
HI ApoE
| \ /  ApoE, tPA, AP,
Brain
C
c 3333
BBB
NPXY 
NPXY
Periphery
515kDa
30-V
Sheddase activity
No transcytosis or 
clearance of Ap
NPXY
NPXY 85kDa
Transcytosis and 
clearance of A(3
Figure 2.1: Full length LRPl facilitates the clearance of Ap through the BBB to the periphery. However, 
proteolytic shedding of LRPl results in the soluble 515kDa fragment, and the cell associated 85kDa 
fragment which prevents the transcytosis of Ap by LRPl. Multiple binding interactions with the 
extracellular cluster areas of LRPl have been identified, many of which are associated with the 
regulation of AP and its production [204]. In addition, the intracellular NPXY tyrosine kinase and 
cytoplasmic domains have been shown to interact with a variety of adapter proteins, such as She, 
disabled and Fe65, which are involved in cellular trafficking and may also be involved in 
transcriptional modulation of its parent protein [157,205,206].
Another m ajor factor affecting the BBB clearance of AP is the interaction w ith  the AP chaperone apoE. 
ApoE is a 34kDa glycoprotein tha t exists as three common isoforms in humans (apoE2, apoE3 and
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apoE4), with the AP0E4 allele (encoding the apoE4 isoform) representing the strongest genetic risk 
factor for AD [160]. Possession of one or two APOE4 alleles increases the chance of developing AD by 4- 
and 15- fold, respectively when compared to APOE3 homozygous individuals[162]. It is well established 
that AD patients and transgenic AD animals homozygous for APOE4 show increased brain AP deposition 
compared to subjects homozygous for APOE3 [163,164]. One of the driving factors behind the increased 
accumulation of Ap in AD is believed to the reduced clearance of Ap from the brain, such as reduced 
clearance of AP through BBB [75,101].This process has also been shown to be influenced by the apoE 
isoforms, with APOE4-targeted replacement mice (APOE-TR) demonstrating reduced AP BBB clearance 
compared to APOE3-TR mice [179].
The ability of LRPl to transcytose AP may be due to its binding interactions with the apoE isoforms (e.g. 
in complex with AP or unbound). Analysis of AD brains showed an increase in binding between apoE and 
AP compared to healthy controls, with samples homozygous for the apoE4 allele demonstrating the 
lowest levels of free apoE compared to other apoE isoforms [207]. These data are also supported by 
results from investigations in murine models, demonstrating that when Ap is bound to apoE, AP 
transport across the BBB is dramatically reduced, with apoE4 mice showing the lowest levels of Ap 
transport from the brain to the periphery [178]. However, as the majority of apoE appears to be 
unbound under physiological conditions, this suggests that apoE is likely facilitative in terms of Ap 
clearance, although conflicting results have also been reported [208]. Experiments previously carried out 
by our group, as well as several others, support the facilitative role of apoE in Ap clearance, with a 
complete absence of apoE significantly reducing the clearance of AP through the BBB and increasing the 
brain AP load [100,179,209,210]. Furthermore, analysis of the levels of apoE in over 100 autopsied 
brains identified an inverse correlation between the apoE levels and the Ap load further supporting the 
beneficial role of apoE with regards to AD [180], Although the mechanism for this altered apoE 
expression has not been established, it is possible that it may be linked to the expression of LRPl, which
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has been shown to reduce the delivery of apoE to lysosomes, thus attenuating apoE degradation [176]. 
ApoE also appears to have altered binding to several proteins that have previously been implicated in 
the shedding of the LRPl [211]. This suggests that while apoE may have a facilitative role in the 
clearance of Ap, it also has potential to contribute to the pathology of AD as a result of its lipidation and 
isoform dependent binding to AP [170].
In light of the recent unsuccessful clinical trials for AD, an improved understanding of the relationship 
between LRPl mediated clearance of AP and the apoE isoforms may pave the way for new avenues of 
therapeutic intervention to combat the cerebrovascular and BBB clearance abnormalities witnessed in 
AD. In particular, knowledge of the mechanisms that are involved in the regulation of LRPl ectodomain 
shedding may be of importance for development of strategies that aim to increase the removal of AP 
from the brain and ultimately reduce the brain Ap load. Therefore, this chapter will investigate the role 
of apoE in the ectodomain shedding and expression of LPR1 as well as its influence on the clearance of 
AP through the BBB using both in vitro and in vivo approaches.
2.2 Methods
2.2.1 Animals
Male APOE-targeted replacement (APOE-TR) mice (4-6 months of age) were purchased from Taconic
Farms (USA). Mice carry one of the three human alleles (APOE2, APOE3, or APOE4) in place of the
endogenous murine APOE gene [212], These mice retain the endogenous regulatory sequences for the
physiological expression of apoE while expressing the human apoE variants in the absence of mouse
apoE. In addition, APOE knockout (APOE KO) mice were generated through disruption of the murine
APOE gene, resulting in a complete absence of the mouse apoE protein [213]. Wild-type mice used in
this study were of the same background (C57BL/6) as the transgenic apoE animals described above.
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Mice were group housed in a temperature and humidity controlled environment on a 12hour light/dark 
cycle with free access to food and water. All the experiments involving mice were approved by the 
Institutional Animal Care and Use Committee of the Roskamp Institute.
2.2.2 Human cortex samples
Human cortex samples from the inferior frontal gyrus for each homozygous APOE genotype were 
acquired from multiple sources as follows: Banner Sun Health Research Institute (Sun City, AZ), the 
University of Maryland (College Park, MD) and the Mount Sinai NIH Brain and Tissue Repository (New 
York, NY). For full information regarding the funding sources and departments involved in these 
institutions, see the acknowledgments section. Demographic information is available in the Appendix 
(Table 9.1).
2.2.3 Preparation of Ap42 peptides
Using a standard protocol to limit aggregation of AP42, both recombinant and fluorescein-AP42 were 
solubilised in l,l,l,3,3,3-hexafluoro-2-propanol to acquire a monomeric/dimeric sample and to reduce 
formation of P-sheet structures as previously described [214]. All experiments involving AP42 utilised 
AP42 peptides prepared in this manner.
2.2.4 Collection and enrichment of human lipidated apoE
Glial cells expressing human apoE2, 3 or 4 isolated from neonatal mice were kindly provided by Dr LaDu 
(University of Illinois at Chicago) [215]. Lipidated apoE particles were collected and enriched from the 
mixed glial cultures as described in our previous work [202]. Briefly, human apoE expressing mixed glial 
cells were plated in 150cm2 flasks (-1.5 brains/flask) in DMEM/F12 (+10% FBS, L-glutamine (2mM), and 
1% penicillin/streptomycin). Upon confluency, cells were washed and incubated with serum-free media 
for 72 hours. Glial-conditioned media was collected and centrifuged at lOOOgfor 3 min to remove any 
residual debris before concentrating (~10x) using the Vivaspin 15R centrifugal concentrator with a 
molecular weight cut-off of 10 000 Da (Sartorius Stedim Biotech, USA). The resulting concentrate was
analysed for apoE content using a human apoE ELISA (MBL International Corporation, USA) and stored 
at -80°C until further analysis.
2.2.5 In vitro LRP1 shedding
Human brain microvessel endothelial cells (HBMECs) (ScienCell, USA) were seeded at approximately 
50,000 cells per cm2 into fibronectin-coated 6-well plates as previously described by our group [216]. 
When approximately 90% confluent, cells were treated with AP42 (2pM), both A042 and one of the 
apoE isoforms (25ng/ml), apoE alone, or left as untreated controls before incubation for 48 hours at 
37°C. AP42 was used at this concentration to minimise fibril formation which occurs with increasing 
concentration [217]. It has been previously been demonstrated that at concentrations lower than 10pM, 
fibril formation was not induced, despite incubation for 1 week under pro-fibril forming conditions 
[218]. Therefore, at 2pM A(342, fibril formation will be kept to a minimum and AP species should remain 
the soluble monomeric and oligomeric states. In addition, several inhibitors were tested to evaluate the 
role of the respective proteases in the shedding of LRP1. These were GI254023X (ADAM10 inhibitor at 
lpM ), SB-3CT (MMP9 inhibitor at lpM ) and a broad spectrum MMP inhibitor (lpM). All stock inhibitors 
were solubilised in 100% DMSO and concentrations of DMSO were <0.1% in all treatment wells. The 
levels of shed LRP1 were assessed in the media via LRP1 ELISA (Cedar Lane Labs, USA) as per the 
manufacturers' instructions. Additionally, a Lactate Dehydrogenase (LDH) assay (Roche Diagnostics, 
Germany) was carried out as per the manufacturers instruction to assess whether AP or a positive 
control, tPA, was inducing cytotoxicity in the HBMECs. As a positive control in the LDH assay, tPA at 
lOnM was included as it is a well established inducer of endothelial stress [219,220].
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Figure 2.2: Dorsal view of mouse skull indicating injection sites for bilateral A042 injections.
2.2.6 Brain LRP1 shedding and Ap BBB clearance in vivo
To examine the effect o f A(3 on the shedding o f LRP1 in vivo, stereotaxic intracranial injections o f A(342 
were performed as previously described [202,221]. Briefly, male APOE-TR or APOE KO mice (4-6  months 
of age) were anesthetized via inhalation using a 4% isoflurane/oxygen mix. While under anesthesia, the 
mice were injected bilaterally w ith  3|il o f vehicle (100% DMSO) or Im M  human A(342 into the caudate 
putamen of each hemisphere o f the brain (0.5mm anterior to  the bregma, 2 mm lateral to  the m idline, 
and 3 mm below the surface o f the skull) w ith  approximately 1 m inute between the bilateral injections 
(Figure 2.2). Ten minutes after the second intracerebral injection, the mice were euthanatized. Upon 
sacrifice, all mouse brains were collected (minus the cerebellum) and the outer vessels and meninges 
were removed using a dry cotton swab [222]. All tissue samples were immediately snap frozen in liquid 
nitrogen and stored at -80°C.
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2.2.7 Brain fraction isolation
Brain fractions were isolated from mouse brains (minus cerebellum and meninges) and human cortex 
samples (from the inferior frontal gyrus) using a technique previously described by our group [202]. 
Briefly, using a Dounce homogenizer, the tissue was homogenized in Hank's Balanced Salt Solution 
(HBSS) on ice. A sample was collected to represent the whole brain homogenate and diluted 1:1 in lysis 
buffer (M-PER + 1%EDTA +0.2%PMSF (Thermo Scientific, USA)) supplemented with Halt protease and 
phosphatase inhibitor cocktail (Thermo Scientific, USA). The remaining homogenized tissue was diluted 
1:1 with 40% dextran followed by centrifugation at 6000g for 15 minutes at 4°C. This resulted in a pellet 
in the base of the tube (cerebrovasculature) and a diffuse mass at the top (parenchyma) which were 
separated by a clear dextran solution (soluble fraction) (Figure 2.3). The parenchymal pellet was 
removed with a cell scraper into a separate tube with the soluble fraction and diluted 1:1 with ice cold 
HBSS. The parenchymal pellet was collected with lysis buffer following centrifugation at 6000g for 5 
minutes. The soluble fraction was centrifuged one final time to remove any remaining debris. All 
samples were immediately stored at -80°C until further analysis by LRP1 ELISA (Cedar Lane Labs, USA). 
Demographics for the human samples can be found in the Appendix (Table 9.1).
2.2.8 Statistical analysis
Where appropriate, significance values were obtained through one-way or two-way ANOVA followed by 
Tukey post-hoc analysis (GraphPad Prism 5, GraphPad Software Inc., USA). Otherwise, where only 2 
groups were compared, unpaired t-tests were utilised. All n values represent technical replicates.
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Figure 2.3: Schematic of the brain fraction separation after the initial centrifugation in 20% dextran for
15 minutes at 6000g with a fixed angle rotor.
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Figure 2.4 : LRPlshedding in HBMECs following exposure to A(342. (A) HBMEC monolayers were 
exposed to human AP42 (0-10pM) for 48 hours at 37°C. Shedding of LRP1 was dose dependent, with 
the highest levels of soluble LRP1 detected at lOpM AP42. (B) Co-treatment of HBMECs with apoE 
(25ng/ml) demonstrated protective effect of the apoE2 and apoE3 isoforms on the shedding of LRP1.
In comparison, co-treatment with the apoE4 isoform did not alter the level of soluble LRP1 when 
compared to cells treated with Ap42 only. LRP1 shedding was assessed by examining LRP1 content in 
the extracellular media using an LRP1 ELISA. Values represent mean ± SEM (n = 5) and are expressed 
as ng of extracellular LRP1 per ml of media. *p<0.05; **p  < 0.01; ****p<0.0001 as determined by one­
way ANOVA followed by Tukey's post-hoc analysis.
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2.3 Results
2.3.1 In vitro shedding of LRP1 after A042 and apoE exposure
To determine the effect of A3 exposure on the shedding of LRP1, we exposed HBMECs to various 
concentrations of A342 for 48 hours. A concentration dependent increase in the production of soluble 
LRP1 was detected in the media with statistically significant increases at concentrations higher than 
2pM A342 (Figure 2.4A). The LDH assay carried out on the cell media from this study identified an 
increase in cytotoxicity in A342 treated cells at concentrations higher than 2pM after 48 hours.
However, A342 treated cells showed significantly lower LDH than the tPA positive control (60% 
reduction) (Appendix:
Figure 9.1). In addition, at the same concentration of tPA, the levels of soluble LRP1 were not 
significantly increased, suggesting that an increase in cell toxicity was likely not a primary factor in the 
generation of soluble LRP1. The influence of apoE on the shedding process was also assessed and 
revealed an apoE isoform-specific effect on the generation of soluble LRP1 (Figure 2.4B). Treatment with 
apoE alone produced a modest increase in soluble LRP1 which did not reach statistical significance when 
compared to untreated controls. Co-treatment of cells with A3 and either apoE2 or apoE3 protected 
LRP1 from Ap-induced shedding with significantly lower levels of soluble LRP1 compared to A3 
treatment alone. In comparison, levels of soluble LRP1 in the apoE4 and Ap co-treated cells were 
significantly higher than the apoE4 only exposures.
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Figure 2.5 : Clearance of A|342 through the BBB and shedding of LRP1 following intracranial injection 
of human A042. (A) APOE-TR and APOE KO mice demonstrated an increase in the shedding of LRP1 
after intracranial injection. The APOE4 mice demonstrated the highest levels of shed LRP1 in both 
treated and naive mice when compared to the other treated and naive APOE genotypes. (B) When 
combined with data previously generated by our lab, an inverse correlation between the shedding of 
LRP1 and the clearance of AP through the BBB was evident (R2= 0.94, p<0.05) [179]. LRP1 shedding 
was assessed by examining LRP1 content in the extracellular media or soluble brain faction using an 
LRP1 ELISA. Values represent mean ± SEM (n = 5) and are expressed as ng of extracellular LRP1 per 
ml. *p<0.05; #p<0.05 in the same genotype,$ p<0.05 compared to all others in treatment group. 
Significance determined by one-way ANOVA followed by Tukey's post-hoc analysis or by Pearson 
correlation analysis.
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2.3.2 In vivo shedding of LRP1
To assess the influence of apoE on the shedding of LRP1 in an in vivo paradigm, mice were injected 
intracerebrally with exogenous human AP42 and the levels of soluble LRP1 measured after processing of 
the brain into fractions (e.g. homogenate, cerebrovasculature and soluble fractions). Similar to our in 
vitro study, exposure to AP42 induced shedding of LRP1 in all APOE-TR genotypes as compared to naive 
APOE-TR mice (Figure 2.5A). However, the level of soluble LRP1 in the naive APOE4 genotype was 
significantly higher than in either the naive APOE2 or APOE3 mice. In addition, the APOE4-TR mice 
treated with Ap also displayed a higher level of soluble LRP1 than the other two APOE isoforms. 
Interestingly, the APOE KO mice showed the least protection of LRP1 from shedding after Ap challenge, 
with significant increase in soluble LRP1 compared to all of the APOE genotypes. These data were 
combined with findings from Bachmeier et al. (2013) - performed prior to the commencement of this 
thesis)) which identified APOE genotype dependent differences in the clearance of Ap after intracranial 
injection [179]. When levels of soluble LRP1 were assessed as a function of AP42 BBB clearance, an 
inverse correlation was observed between LRP1 shedding and AP BBB clearance (Figure 2.5B). 
Unfortunately, the clearance study did not include APOE2-TR mice. In its absence, APOE3-TR mice 
showed the highest level of Ap42 BBB clearance and lowest levels of soluble LRP1. In comparison, the 
APOE-KO mice showed the lowest levels of AP BBB clearance and the highest soluble LRP1.
2.3.3 Expression and shedding of LRP1 in the human cortex fractions
To assess whether our in vitro and in vivo findings translated to the human population, we assessed the 
levels of LRP1 in cortex samples from the human inferior frontal gyrus. In the homogenate, total LRP1 
was significantly higher in the ND group with approximately a 1.8-fold increase over the AD group 
(Figure 2.6A). When stratified by APOE genotype, APOE4/4 individuals in the ND group demonstrated 
significantly higher levels of total brain LRP1 compared to other ND APOE genotypes (Figure 2.6B). In 
addition, the levels of total LRP1 in the ND APOE3/3 and APOE4/4 group were also approximately 2-fold 
higher than those seen in the equivalent AD group. No significant change in the levels of soluble LRP1
were observed when assessed by disease state or when stratified by APOE genotype and disease state 
(Figure 2.6C). Expression of membrane associated LRP1 in the cerebrovascular fraction was 
approximately 2-fold higher in the ND samples when compared to the AD samples (Figure 2.6D). When 
stratified by APOE genotype, it was revealed that the levels of LRP1 were significantly altered by both 
the disease state and the APOE genotype (Figure 2.6E). While LRP1 levels in the vasculature were 
consistently higher in the ND compared to AD samples in all genotypes, with at least a 2-fold increase, 
significance was only reached in the APOE4/4 individuals. In addition, the APOE4/4 ND group showed 
significantly higher LRP1 expression in the vascular fraction than the APOE2/2 ND group.
2.3.4 Inhibition of LRP1 sheddases in HBMECs
Exposure of HBMECs to both AP42 and the MMP9 selective inhibitor SB-3CT or ADAM10 selective 
inhibitor GI254023X significantly reduced the levels of soluble LRP1 when compared to AP42 only 
treated cells (Figure 2.7). Levels of soluble LRP1 in SB-3CT and GI254023X treated cells were reduced to 
levels similar to those seen in the controls and were 50% and 60% of the Ap treated cells respectively. 
The broad-spectrum MMP inhibitor lowered the levels of soluble LRP1 by approximately 25% compared 
to AP only treated cells but failed to reach statistical significance.
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Figure 2.6 : Expression profiles of LRP1 in the human cortex and cerebrovasculature. (A) Expression of 
total brain LRP1 was significantly lower in individuals with AD when compared to non-demented 
controls. (B) This was found to be apoE dependent, with the apoE4 non-demented samples showing 
an elevated LRP1 expression compared to the other APOE genotypes. In addition, AD APOE4/4 
samples showed significantly lower LRP1 expression when compared to the APOE4/4 non-demented 
controls. (C and D) No significant changes were detected in the levels of soluble LRP1 in the soluble 
brain fraction between non-demented and AD samples or when stratified by APOE genotype. (D) 
Levels of LRP1 in the cerebrovasculature were significantly lower in the AD samples when compared
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to the non-demented controls. (E) This effect was apoE and disease dependent, with non-demented 
APOE4/4 samples showing the highest levels of LRP1 compared to the other APOE genotypes. In 
addition, AD APOE4/4 samples were significantly lower than the APOE4/4 non-demented controls. 
LRP1 expression was assessed by LRP1 ELISA. Values represent mean ± SEM and are expressed as ng 
of LRP1 per mg protein or ng soluble LRP1 per ng total LRP1. *p<0.05; **p<0.01; ****p<0.0001; 
#p<0.05 in the same genotype. Significance determined by Student's t-test or two-way ANOVA 
followed by Tukey's post-hoc analysis.
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Figure 2.7 : Inhibition of LRP1 shedding in HBMECs. The shedding of LRP1 in HBMECS was reduced by 
treatment with a broad spectrum MMP inhibitor (marimastat), an MMP9 specific inhibitor (SB-3CT) 
and an ADAM10 specific inhibitor (GI254023X). LRP1 shedding was assessed by examining LRP1 
content in the extracellular media using an LRP1 ELISA. Values represent mean ± SEM (n = 3) and are 
expressed as ng of extracellular LRP1 per ml of media. *p<0.05; as determined by one-way ANOVA 
followed by Tukey's post-hoc analysis.
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2.4 Discussion
Transport of AP through the BBB by the lipoprotein receptor LRP1 is considered one of the main routes 
by which AP is removed from the brain. While most receptors in the lipoprotein family are capable of 
transporting AP, LRP1 endocytoses AP at a much faster rate, and is therefore considered the primary 
route [223]. In support of this, endothelial KO of LRP1 in mice results in a large reduction in the BBB 
clearance of Ap and increased Ap brain load [123]. Interestingly, it has previously been reported that 
levels of the functional membrane associated LRP1 is lower in individuals with AD [138]. However, the 
precise mechanism behind the reduced presence of LRP1 in AD is still not understood. Our current 
findings suggest the ectodomain shedding of full length LRP1, resulting in a non-functional soluble LRP1, 
may be one of the mechanisms by which expression is reduced. An understanding of what drives these 
mechanisms could pave the way to pharmacological interventions that increase the levels of full length 
LRP1 by blocking these shedding mechanisms, thereby reducing the brain Ap load as a result of 
increased BBB clearance.
We demonstrate that Ap42 induces shedding of LRP1 in both in vivo and in vitro conditions. In addition, 
when these data were combined with Ap clearance data previously produced by Bachmeier et al. (2013) 
an inverse correlation was observed between the clearance of AP to the periphery and the levels of 
Ap42 induced shedding of LRP1 in APOE-TR mice [179]. This suggests that the shedding of LRP1 may be 
one of the mechanisms responsible for the reduced AP clearance from the brain witnessed in AD and as 
a result of the APOE allele present.
The binding of apoE to Ap has previously been shown to be an important factor in the clearance of Ap 
through the BBB [179]. In comparison to unbound Ap, AP bound to apoE was found to be cleared at a 
significantly slower rate. However, Verghese et al. demonstrated that under physiological conditions 
where the apoE protein is lipidated, the binding of Ap to apoE is minimal, with only 6% of AP bound to 
apoE3 after 12 hours of incubation [208]. In addition, the rate in which AP and apoE3 associated slowed
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significantly after the initial two hours and began to form a plateau. In our in vitro study investigating 
the shedding of LRP1, although the concentration of apoE utilised was slightly higher than those in the 
studies by Verghese et al., we believe that the percentage of AP bound to apoE would remain minimal 
and we are therefore witnessing the effect of mostly unbound apoE on the clearance AP and shedding 
of LRP1. However, there are several limitations to the use of the lipidated apoE as a result of the 
methodology used obtain the protein. For instance, the apoE is in an enriched cell culture media, with 
size exclusion used to removal proteins smaller than lOkDa.Therefore the apoE solution contains 
proteins larger than this that may interfere with the mechanisms being investigated, such as the 
shedding of LRP1. However, the apoE only treatment in HBMECs showed no significant effect on the 
shedding of LRP1 and the effects observed appear to be as a result of an interaction between apoE and 
AP42. It is therefore unlikely that this mechanism is driven by another protein as the effects seen are 
specific to each of the APOE isoforms.
APOE4 remains the strongest genetic risk factor for developing AD and, despite its identification over 20 
years ago, very little progress has been made towards establishing a definitive mechanism by which it 
appears to be less efficient than apoE2 or apoE3 in protecting from the development of AD. While 
several groups have investigated the expression of LRP1 and its relationship to total apoE levels, few 
have factored in the possibility of an isoform dependent relationship [224,225]. Of those that have 
accounted for the apoE isoform, conflicting results have been published detailing changes in LRP1 
expression and mRNA levels depending on the apoE isoform present. For instance, both lower and 
higher levels of LRP1 expression has been reported in the APOE4 genotype in comparison to other 
genotypes [226,227]. Our investigation indicates that the APOE genotype influences expression of LRP1 
in the cortex and in the cerebrovasculature. There was also a disease state dependent effect in levels of 
total LRP1, with the ND APOE4/4 sample showing by far the highest level. Analysis of the membrane 
associated levels of LRP1 in the vascular fraction, and therefore the most relevant in terms of BBB 
clearance of Ap, revealed similar results to the total LRP1 levels, with both APOE genotype and disease
dependent effects. In all cases, the level of LRP1 in the vasculature was higher in the ND samples. When 
the results were pooled to assess disease state differences in all samples, the ND samples showed 
significantly higher levels of LRP1 in the vasculature. As membrane associated LRP1 is primarily 
responsible for the clearance of A3 through the BBB, these data provide rationale for prior reporting 
that the clearance of Ap is reduced by as much as 30% in AD [75]. However, one confounding factor 
which should be acknowledged when interpreting this data is that the ND APOE4/4 individuals had a 
lower average age than their AD counterparts. Therefore, some of the AD effects we witness may be 
due to this disparity in age or may even show a pre-AD phenotype in these individuals. It should also be 
noted that the expression of LRP1 in the cerebrovasculature appears to be much higher than the 
parenchyma when standardised to total protein, with approximately 100-fold more LRP1 per mg protein 
compared to the total homogenate.
Interestingly, the human samples showed no significant differences in the levels of soluble LRP1,
suggesting that the ectodomain shedding of LRP1 may not be a pathological driver of AD. However, all
our in vivo and in vitro analysis, as well as the work of others, suggests that shedding of LRP1 is
exacerbated in an A3 rich environment [146]. Therefore, it is possible that we were just unable to detect
the changes in soluble LRP1, perhaps as a result of other proteins from the soluble fraction binding to
LRP1 and masking the epitope. However, even if the levels of ectodomain shedding of LRP1 are not
increased in AD or by the APOE genotype, shedding of LRP1 still occurs. In addition, maintaining higher
levels of full length LRP1 appears to be beneficial, with ND individuals consistently demonstrating higher
levels of membrane associated LRP1. Therefore, reducing the ectodomain shedding of LRP1 may still be
a viable strategy as it could restore the levels of functional LRP1 and facilitate A3 clearance regardless of
the APOE genotype, especially in the vasculature where it would enable removal of A3 to the periphery.
In addition, restoring LRP1 expression may have other positive effects. Investigational therapies, such as
bexarotene, which has been shown to reduce brain A3 load and improve cognition, appear to be reliant
on LRP1 expression to induce their beneficial effects [228]. In addition, several approaches have been
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taken to increase the expression of LRP1 such as the PPARy activator Rosiglitazone, which was capable 
of almost doubling the expression of LRP1 in HBMECs. However, the use of Rosiglitazone in a clinical 
setting is hampered by the relatively small therapeutic window for its efficacy [197]. Therefore, 
inhibition of the proteases responsible for the ectodomain shedding of LRP1 may be a more preferable 
approach. We demonstrate that inhibition of the sheddases ADAM10 and MMP9 successfully reduced 
the A3-induced shedding of LRP1 which has previously been reported by other groups [146,229]. While 
these are only preliminary results, and the actions of these proteins will be further investigated in 
Chapters 4 and 5 where their potential for pharmacological targeting will be assessed.
Peripheral soluble LRP1 has previously been demonstrated to play a major role as a peripheral sink for 
A3, binding between 70-90% of circulating A3 [130]. It has also been demonstrated that the ability of 
soluble LRP1 to function in this manner may be reduced in AD, which may also contribute to the 
increased influx of A3 into the brain via the RAGE receptors in the cerebrovasculature [130]. In this 
respect, the shedding of LRP1 and the presence of soluble LRP1 in the periphery may be advantageous 
in increasing clearance of A3 reducing the brain A3 load that would be impacted by inhibition of LRP1 
sheddases. However, this sink mechanism is reliant upon on a functional BBB clearance mechanism for 
A3 to enable it to reach the periphery. Therefore, the positive effects of the soluble LRP1 sink is 
rendered obsolete if A3 is unable to be transported out of the brain. In light of this, we believe the 
restoration of BBB clearance mechanisms and prevention of LRP1 shedding in the endothelial cells 
should be a primary target for removal of A3 to the periphery, and that it remains a viable approach to 
reduce the burden on A3 on the brain.
In addition to the altered shedding and expression hypothesis outlined above, another explanation for 
the changes in transcytosis of A3 through the BBB may be that the intracellular trafficking mechanisms 
responsible for the movement of A3 are somehow altered or dysfunctional in AD. As apoE appears to 
alter the rate at which A3 is transcytosed across the BBB, it is possible that these mechanisms are
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sensitive to the apoE isoform present. Indeed, intracellular trafficking in various cell types has previously 
has been shown to be dependent on the apoE isoforms [230-232]. However, the bulk of this work has 
been conducted in neuronal and microglial cells. Therefore, Chapter 3 will investigate altered 
intracellular trafficking of A3 in HBMECs as a result of the different apoE isoforms.
In summary, this chapter builds on the previously established hypothesis that reduced expression and 
function of LRP1 may be a contributing factor that drives the pathology of AD. As such, restoration of its 
clearance activity may prove beneficial in reducing the A3 pathology. This chapter also links the 
expression of LRP1 and A3 clearance through the BBB with the well known AD risk factor, APOE4. A 
better understanding of the mechanisms involved in the clearance of A3 through BBB and the role in 
which apoE plays in this process may provide rationale for the failures of many AD clinical trials. For 
instance, previous clinical trials may have been ineffectual as a result of dysfunctional clearance of A3 
through the BBB masking the effects of the treatment, and not as a result of a lack of target efficacy. 
However, to effectively increase the expression of full length LRP1 at the BBB, a better understanding of 
the mechanisms that control its expression, such as the sheddases, will be necessary. Our in vitro and in 
vivo studies clearly demonstrate a strong inverse relationship between the ectodomain shedding of 
LRP1 and the clearance of A3 through the BBB. In addition, we demonstrate that this relationship is 
apoE isoform dependent. We also identify apoE dependent changes in expression of LRP1 in the brain 
and the vasculature and found the LRP1 expression was reduced in both cases. To our knowledge, this is 
the first time AD and APOE dependent changes in the expression of LRP1 in the cerebrovasculature has 
been assessed. The results clearly indicate that APOE influences the expression of LRP1 and that the 
mechanisms involved in LRP1 regulation at the BBB may be dysfunctional in AD. As such, targeting these 
mechanisms may provide novel approaches to treating AD, particularly individuals with the APOE4 
allele. The subsequent chapters will evaluate several mechanisms to further describe the observations 
presented here.
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Chapter 3 : ApoE dependent uptake and subcellular localisation of Ap
3.1 Introduction
Alzheimer's disease (AD) is characterised by the accumulation of amyloid 3 (A3) peptides both intra- and 
extra-cellularly. The clearance of Ap has been shown to be reduced in AD by as much as 30%, suggesting 
that the mechanisms involved in the uptake, endocytosis and transcytosis of A3 may be dysfunctional 
[75]. Transcytosis of Ap through the BBB to the periphery requires three separate and distinct processes: 
(1) receptor mediated endocytosis of A3 at the basolateral side of the BBB; (2) intracellular endocytic 
trafficking of the protein through the endosomal compartments and (3) the subsequent exocytosis of AP 
at the apical side resulting in the release of A3 to the periphery. It has therefore been that suggested 
that dysfunctional endosomal trafficking may be a contributing factor to both the intracellular 
accumulation of A3 [2,233].
Perturbed intracellular trafficking has previously been implicated as an early contributor to AD 
pathology. For instance, altered expression of critical proteins involved in endosomal sorting and 
maturation appear to correlate with the early signs of AD [234,235]. There is also evidence of defective 
endosomal function in later-stage AD and in AD animal models, with high levels of A342 found in 
neuronal bodies resulting in synaptic dysfunction, deficits in longterm-synaptic plasticity, and dystrophic 
neurons prior to the onset of A3 plaque pathology [236-238]. Under non pathological conditions in 
neurons, Ap is generated intracellularly at the endoplasmic reticulum where it is then transported to the 
trans-Golgi network (TGN) before being introduced into the endosomal system and finally being 
released into the extracellular environment [239-241]. In AD, it is believed the build up of intracellular 
Ap may be a result of increased Ap retention due to defective intracellular trafficking [242,243]. In 
support of this, recent genome wide association studies identified several endocytosis and trafficking- 
related genes, such as BIN1, CD2AP, PICALM and CD33, that correlate with the occurrence of AD and are 
likely to be risk factors [69,244-246].
The majority of endocytic receptors and proteins are trafficked through several well defined intracellular 
compartments before being delivered to lysosomes for degradation or recycled back towards the 
membrane. The individual endocytic compartments can be differentiated through members of the rab 
(ras related protein) GTPase family which play critical roles in controlling vesicular transport between 
compartments. For instance, rab5 is associated with early endosomes, and in conjunction with the early 
endosome antigen 1 (EEA1), allows the fusion of endosomes which is required for the formation of 
other species of endosomes and progression of proteins through the endosomal trafficking pathway 
[247]. The other main endosomal compartments include the late endosomes, characterised by rab7, 
which are responsible for movement of proteins to the lysosomal compartments for degradation, and 
the recycling endosomes, characterised by ra b ll,  which are responsible for the trafficking of proteins 
back to the cell membrane. While the exact compartments involved in the transcytosis of Ap across the 
BBB were not, until recently, very well defined, studies by Zhao et al. have demonstrated that 
transcytosis of Ap requires the function of both the early (EEA1 or rab5) and recycling (rab ll) 
endosomes with mutant varieties of each demonstrating significantly reduced A3 transport across a 
polarised membrane [248]. In contrast, mutant forms of the late endosome, rab7, resulted in only very 
modest reductions in A3 transcytosis.
As previously mentioned, clearance of Ap through the BBB is believed to be reduced in AD. There are
also, there are indications that this process may also be dependent on the apoE isoform present
(Chapter 2) [177,179,202]. We propose that one or more of the three processes required for the
transcytosis of Ap in endothelial cells (e.g. endocytosis, endocytic trafficking or exocytosis) is sensitive to
the apoE isoform. Indeed, several studies have identified apoE isoform dependent differences in the
endocytic trafficking of Ap. For example, neuronal cells exposed to the apoE3 isoform are more efficient
at transporting AP to lysosomal compartments compared to apoE4 treated cells [230]. It has also been
demonstrated that the apoE2 isoform does not facilitate the uptake of Ap into neuroblastoma cells in
contrast to the apoE3 and apoE4 isoforms [231]. These interactions, in combination, may result in an
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increased accumulation of intracellular A3 with apoE4 compared to the other isoforms [232], potentially 
as a result of the reduced cellular uptake with apoE2 and increased lysosomal degradation with apoE3. 
However, the bulk of this work has been conducted in neuronal and microglial cells and not in brain 
endothelial cells and under the context of transcytosis through the BBB. As such, this chapter will 
investigate the uptake and intracellular trafficking of A3 in the presence of different apoE isoforms in 
HBMECs. This mechanism will be investigated to potentially explain the altered clearance of A3 through 
the BBB described in Chapter 2.
3.2 Methods
3.2.1 Antibodies
Immunohistochemical studies were carried out with the following antibodies: rabbit anti-human EEA1 
(alexa fluor 647conjugated monoclonal (abl96186, Abeam, USA)), rabbit anti-human ra b ll (polyclonal, 
(ab3612, Abeam, USA)), donkey anti-rabbit IgG (alexa fluor 647 conjugated polyclonal (abl50075 Abeam, 
USA)), rabbit anti-human LRP1 (alexa fluor350 conjugated polyclonal (bs-5409R-A35, Bioss, USA)).
3.2.2 Preparation of Ap42 peptides
A342 peptides were prepared in an identical method as previously described in Chapter 2 (section
2.2.3).
3.2.3 Collection and enrichment of human lipidated apoE
Lipidated apoE was collected as previously described in Chapter 2 (section 2.2.4).
3.2.4 ApoE dependent uptake of Ap42 into HBMECs
Human Brain Microvascular Endothelial Cells (HBMECs) (ScienCell, USA) were seeded into fibronectin- 
coated 96-well black sided clear bottomed plates and grown in endothelial cell media (ECM) (5% FBS, 5% 
penicillin/streptomycin, 5% endothelial cell growth serum) (ScienCell). When approximately 90%
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confluent, cells were treated with lipidated apoE isoforms (5-50ng/ml) and fluorescein-Aj342 (2pM) and 
incubated for 2 hours at 37°C. Following incubation, cells were washed with cold PBS and fixed with 5% 
PFA. Cell associated A3 was assessed using a BioTek HT Synergy multidetection microplate reader at 
488/515 Ex/Em.
3.2.5 Detection of Intracellular LRP1 in HBMECs after Ap treatment
HBMECs were seeded into fibronectin-coated 96-well black sided clear bottomed plates and grown in 
ECM (5% FBS, 5% penicillin/streptomycin, 5% endothelial cell growth serum). When at approximately 
90% confluency, cells were treated with lipidated apoE isoforms (25ng/ml) and/or A342 (2pM) before a 
2 hour incubation at 37°C. Following incubation, cells were washed with cold PBS and fixed with 5% PFA 
before permeabilisation of cells with 0.5% Tween 20 for 15 minutes. An anti-LRPl antibody (1:200) was 
used to assess the levels of LRP1. The total internalised LRP1 was obtained by subtracting value for the 
surface LRP1 levels in non-permeabilised cells from the total LRP1 levels in the permeabilised cells. 
Detection measurements were carried out using a BioTek HT Synergy multidetection microplate reader 
at 350/440 Ex/Em.
3.2.6 ApoE dependent colocalisation of Ap with endosomal compartments
HBMECs were seeded onto 8-well chamber slides and grown in ECM 5% FBS, 5% penicillin/streptomycin, 
5% endothelial cell growth serum). When approximately 90% confluent, cells were treated with 
25ng/ml lipidated apoE. After 24 hours incubation, fluorescein-labelled A342 was spiked in (2pM) and 
cells were incubated at 37°C for 1 hour. Following incubation, cells were washed with cold PBS and fixed 
in 100% methanol (EEA1; 5 minutes) or 4% PFA (rab ll; 15 minutes) before permeabilisation in 0.3% 
Triton X-100 for another 5 minutes. Cells were subsequently blocked with 1% FBS, 10% Donkey 
serum/0.3M glycine and 0.1% PBS/Tween 20 (ra b ll only) for 1 hour before incubation with primary 
antibodies overnight at 4°C (EEA11:50, ra b ll 1:200),. When necessary, cells were washed and 
incubated with the secondary antibody (alexa fluor 647 conjugated donkey anti-rabbit IgG, 1:200) for 2
hours at room temperature. Otherwise, all slides were washed with PBS before mounting with 
Fluoroshield mounting media with DAPI (Sigma Aldrich, USA). All were single images and were taken 
with a Zeiss LSM 800 confocal microscope (Zeiss, Germany). For imaging and quantification analysis, 5 
randomly selected images were used from each biological replicate. Colocalisation coefficients, 
endosome size, and area coverage were assessed using Zen blue edition 2.1 software (2011) (Zeiss, 
Germany).
3.2.7 Statistical analysis
Where appropriate, significance values were obtained through one-way or two-way ANOVA followed by 
Tukey post-hoc analysis (GraphPad Prism 5, GraphPad Software Inc., USA). Otherwise, where only 2 
groups were compared, unpaired t-tests were utilised. Unless otherwise indicated, all n values represent 
technical replicates.
3.3 Results
3.3.1 ApoE dependent uptake of Ap
Uptake of AP into cultured endothelial cells was found to be apoE dependent, with apoE3 and apoE4 
displaying the highest levels of cell associated Ap (cell surface and internalised) after a 2 hour treatment 
(Figure 3.1). The lowest levels of cell associated A3 in was detected in cells treated with 50ng/ml apoE2 
and was approximately 40% lower than the untreated controls and was significantly lower than the 
apoE4 treated cells.
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Figure 3 .1 : Uptake of fluorescein-Ap42 in HBMECs with different apoE isoforms. HBMECs were 
exposed to apoE isoforms (5-50ng/ml) and fluorescein-Ap42 (2pM) for 2 hours and the level of cell 
associated fluorescein-Ap42 measured. Cells exposed to apoE4 demonstrated a significantly higher 
levels of cell associated fluorescein-Ap42 when compared to apoE2 treated cells at 50ng/ml apoE. In 
addition, apoE2 treated cells showed a reduction of cell associated fluorescein-Ap42 when compared 
to the untreated control. Values represent mean ± SEM (n = 3) and are expressed as mean fluorescent 
units. *p<0.05 as determined by one-way ANOVA followed by Tukey's post-hoc analysis.
3.3.2 The level of intracellular LRP1 is apoE isoform dependent 
The levels o f intracellular LRP1 after exposure to  AP was found to  be apoE isoform dependent 
(apoE2<apoE3<apoE4) (Figure 3.2). Levels o f intracellular LRP1 in the apoE only cells were consistently 
lower than in the cells exposed to  both apoE and Ap. However, only apoE3 and apoE4 exposed cells 
reached statistical significance. In the control cells (no apoE exposure), trea tm ent w ith  Ap did not 
appreciably a lter the levels o f intracellular LRP1, and was the only trea tm ent group tha t showed a 
reduction, albeit only modestly, in the levels of intracellular LRP1. However, the untreated controls (no
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A(3 trea tm ent or apoE) showed significantly higher levels o f intracellular LRP1 compared to  all o f the 
apoE treated cells.
I------------------------1 *
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Figure 3.2 : Levels of intracellular LRP1 after exposure of HBMECs to apoE and AP42. ApoE isoform 
dependent levels of intracellular LRP1 was observed with apoE4 demonstrating the highest levels of 
internalised LRP1 after exposure to AP42. Treatment induced significant increases in the amount of 
intracellular LRP1 in both the apoE3 and apoE4 treated cells compared to the respective control. In 
addition, cells with no apoE showed higher levels of intracellular LRP1 compared to all apoE isoforms 
in the absence of AP42. Values represent mean ± SEM (n = 8) and are expressed as mean fluorescent 
units. *p<0.05, ****p<0.0001,$ p< 0.05 compared to all other conditions in the treatment group, 
*p<0.01 between treatment and respective control. Statistics determined by two-way ANOVA 
followed by Sidak post-hoc analysis.
3.3.3 Colocalisation of Ap with EEA1 and r a b l l  endosomal markers
Areas tha t stained positive w ith the EEA1 marker showed high levels o f association w ith  Ap. In addition,
this interaction was found to  be apoE dependent, w ith  EEA1 positive areas and Ap colocalisation the
lowest in apoE2 treated cells and highest in the untreated controls (apoE2<apoE3<apoE4<control)
(Figure 3.3 A and B). The fraction of the to ta l cell associated AP tha t was localised w ith  EEA1 positive
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areas (Ap-EEAl colocalisation coefficient) was lowest in the control and apoE2 treated cells and highest 
in the apoE4 treated cells (apoE2<control<apoE3<apoE4) (Figure 3.3 A and C). In contrast, no significant 
differences in the colocalisation of the recycling endosomal marker, ra b ll, with Ap were observed 
(rabll-Ap colocalisation coefficient). Similarly, the amount of Ap that was associated with the areas 
positive for recycling endosomes was not affected by the apoE isoform present (AP-rabll colocalisation 
coefficient) (Figure 3.4 A-C).
3.3.4 Quantification of EEA1 and r a b l l  endosome number and size
ApoE dependent effects on the both the number and size of the EEA1 positive early endosomes were 
observed (Figure 3.3 A, D and E). ApoE2 treated cells showed the lowest number of EEA1 early 
endosomes (control=apoE2<apoE3<apoE4) in addition to the endosomes being significantly smaller than 
those in the apoE3 and apoE4 treated cells (control=apoE2<apoE3=apoE4). In comparison, no significant 
differences in the size or number of ra b ll positive recycling endosomes were detected between the any 
of the apoE treatments (Figure 3.4 A, C and D).
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Figure 3.3 : ApoE isoform-dependent impact on EEA1 positive early endosomes and AP42 trafficking. 
(A) HBMECs were exposed to apoE (25ng/ml) for 24 hours before treatment with fluorescein-A[342 
(2pM) for 1 hour. (B) The fraction of EEA1 positive early endosomes that contained AP42 was apoE 
dependent with the control and apoE4 isoform treat cells demonstrating the highest EEA1-AP42 
colocalisation. (C) In addition, there was an increase in the fraction of total cell associated Ap42 that 
was colocalised with EEA1 in the apoE4 isoforms when compared to apoE2, apoE3 and the control 
cells. (D) The number of EEA1 positive early endosomes was higher in cells in an apoE4 environment 
compared to all other apoE isoforms and the control. (E) In addition, early endosomes were 
significantly larger in the apoE3 and apoE4 treated cells in comparison to the apoE2 treated cells.
Scale bar (located on DAPI/EEA1/Ap42 apoE4 treated panel) represents 50pm. Values represent mean
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± SEM (n = 5 technical replicates from each of the 3 biological replicates). *p<0.05, **p<0.01, 
***p<0.001 as determined by one-way ANOVA followed by Tukey's post-hoc analysis.
3.4 Discussion
The accumulation of A3 that is found in the AD brain may be the result of reduced or dysfunctional A3 
clearance [75]. One of the major routes of clearance of A3 from the brain is through the BBB with at 
least 25% of total clearance reliant on this route [101]. This process requires the initial uptake of A3 into 
the cell, via receptors such as LRP1, and endocytic trafficking leading to the eventual release of the cargo 
at the apical side of the BBB into the plasma.
As previously discussed, the presence of the APOE4 allele is a major risk factor for the development of
AD. Multiple studies have shown an association between APOE4 and A3 levels in the brain and as such,
is strongly implicated in the development AD pathology and the onset of disease. In contrast, the APOE2
allele is associated with a lowered risk of developing AD in comparison to the APOE3 allele and appears
to confer a protective effect with regards to A3 pathology. We initially investigated whether the
internalisation A3 in endothelial cells was altered by the presence of the different apoE isoforms.
Interestingly, we found that apoE2 significantly reduced the amount of A3 associated with the cells. In
addition, this was supported by experiments which showed reduced internalisation of LRP1 in HBMECs
after treatment with A342 in cells exposed to apoE2 when compared to the other apoE isoforms. While
this at first appears to contradict the transcytosis data outlined in Chapter 2, with apoE2 resulting in the
highest levels of transcytosis and apoE4 the lowest, closer inspection of the subcellular localisation of A3
suggests that subcellular trafficking may be a confounding factor that could help explain this apparent
contradiction. It is also possible that the reduced internalisation of A3 and LRP1 in the apoE2 treated
cells could also be attributed to an increase in the rate of receptor or ligand recycling. Under this
scenario the rate of internalisation would be more closely matched by the rate of exocytosis in the
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Figure 3.4 ApoE-isoform dependent impact on ra b ll positive recycling endosomes and Ap42 
trafficking. (A) HBMECs were exposed to the apoE isoforms (25ng/ml) for 24 hours before treatment 
with fluorescein-Ap42 (2pM) for 1 hour. (B) Treatment of cells with apoE did not significantly alter the 
number of recycling endosomes that contain Ap42 or (C) the fraction of total cell associated Ap42 that 
was colocalised with the ra b ll positive recycling endosomes. In addition, neither (C) the number or 
(D) size of the ra b ll positive endosomes was significantly altered by the presence of the different 
apoE isoforms. Scale bar (located on DAPI/rabll/AP42 apoE4 treated panel) represents 50|im. Values 
represent mean ± SEM (n = 5 technical replicates from each of the 3 biological replicates) and 
statistical significance assessed via one-way ANOVA.
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apoE2 cells. Conversely, under apoE4 conditions, the rate of recycling may be slower, leading to an 
intracellular accumulation of Ap. However, under this experimental paradigm, it is impossible to 
conclusively state which of these two explanations is correct.
It has previously been demonstrated that both early and recycling endosomal compartments are 
required for the efficient transcytosis of Ap across the BBB [248]. In AD, both neurons and fibroblasts 
show early endosome dysfunction which is characterised by both an increase in number and size of early 
endosomes [249-251]. Furthermore, increases in the expression of early and late endosomal markers 
were detected in the hippocampus of brains from patients with mild-cognitive impairment (MCI) and AD
[252]. This increase in endosomal markers was found to correlate with cognitive decline, suggesting it 
may be an early pathological event in the development of AD [235]. In our study, we observed an 
increase in the number of early endosome positive areas in endothelial cells in the apoE3 and apoE4 
treated cells compared to the apoE2 cells. This suggests that the pathologies associated with increased 
early endosomal accumulation, which based on the available evidence appears to be fairly ubiquitous 
between cell types, may be influenced by the apoE isoform that is present. In addition, an increase in 
the size of the early endosome positive area was also detected in the apoE3, apoE4 and control (no 
apoE) endothelial cells compared to the apoE2.
Although not previously identified in endothelial cells, the role of dysfunctional endosomal transport in 
the early stages of AD has been highlighted in studies carried out by Cataldo et al. who demonstrated 
that differences in the size of endosomes in neurons. In addition, these endosomal abnormalities were 
accelerated by the apoE4 allele at the earliest stages of disease, but not in moderate to severe stages
[253]. Furthermore, knockdown of proteins involved in the control of the late endosomes in neuronal 
like cells prevented trafficking of Ap to the lysosomal compartments, resulting in enlargement of the 
early endosomes and accumulation of AP in the early endosomes, similar to that witnessed in our study
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[254]. This suggests that the enlarged early endosomes may occur as a result of an inability to efficiently 
traffic protein cargo to the next appropriate endosomal compartment. The enlarged endosomes in our 
study are colocalised with A3, suggesting that A3 peptides may be accumulating in these swollen early 
endosomes. If this change in number and morphology of early endosomes is revealed to be a 
pathological driver, it suggests that the both the absence of any apoE isoform, or the presence of the 
apoE3 and apoE4 isoforms may be detrimental to endosomal trafficking of A3 in the cerebrovasculature 
and would therefore impact the BBB clearance of Ap. In contrast, it has previously been suggested that 
the increase in number and size of early endosomes may be a compensatory mechanism that occurs due 
to the elevated levels of Ap found in the AD brain [250]. However, our study suggests that this is not the 
case, as all cells received the same amount of A3 and the pathology was only reproduced in the control, 
apoE3 and apoE4 treated cells.
In addition, other abnormalities in the composition of the early endosomes have also been noted in AD. 
In particular, high levels of the proteases Cathepsin B and D, which are normally concentrated in the 
lysosomal compartments, are found in the early endosomes of neurons in regions with increased levels 
of Ap [255,256]. While it has not yet been established whether the change in localisation of these 
proteases is a driver of pathology, or simply a reaction to increased endocytosis of A3 in AD, there are 
indications that Cathepsin is detrimental to memory tasks in AD animal models. For instance, Cathepsin 
deletion in an AD mouse model significantly improved learning and memory retention while also 
reducing the brain A3 load. Therefore, the increased expression of Cathepsin may be a contributor to AD 
pathology [257].
The efficient transcytosis of Ap also relies on the recycling endosomes, characterised by the expression 
of ra b ll [248]. While the majority of research in the AD field has focused on the dysfunction of early 
and late endosomes, there are also indications that the activity of the recycling endosomes may also be 
impaired. For instance, the expression of rab4, a marker for rapid recycling endosomes, is upregulated in
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MCI and in AD [235]. This upregulation of rab4 was observed in the MCI cohort when compared to 
cognitively normal controls. In addition, no change in rab4 expression detected between the MCI and AD 
groups, suggesting that this may be one of the early pathologies associated with the development of 
MCI prior to the conversion to AD [235]. However, in our study, we observed no significant difference in 
the size or morphology of the ra b ll positive recycling endosomes. In addition, there was also no apoE 
dependent effect on the colocalisation of A3 with ra b ll or the number of ra b ll endosomes that 
contained A3- However, while the ra b ll recycling endosomes appear unaffected by the apoE isoforms 
preset, it is possible that the rapid recycling endosomal compartments which were found to be altered 
by MCI and AD, as characterised by the rab5 protein, are sensitive to the apoE isoforms which may 
explain some risk conferred by the APOE4 gene [235].
In summary, evidence from these studies suggest that the apoE4 isoform causes an increase in the levels
of internalised Ap which does not correspond with an increase in the transcytosis of A3 across the BBB,
actually resulting in the slowest clearance across the BBB (as outlined in Chapter 2). Therefore, the rate
in which Ap is shuttled through the endosomal compartments after its initial internalisation must be
slower in the apoE4 environment compared to the apoE2. This may help explain the observation for
reduced internalisation of A3 in an apoE2 environment as the recycling may be quicker, resulting in a
reduced backlog of Ap. We hypothesise that the enlarged early endosomes detected with the apoE4
isoform, which have also been observed in the AD brain, may be the result of this slower trafficking of
Ap between the early and the recycling endosomes [253]. However, due to the design of this study, with
only a final endpoint assessment of the intracellular trafficking, we were not able to assess any changes
in the rate of A3 transport. Regardless, it is clear that while more internalised A3 is associated with the
presence of apoE4 or in the absence of any apoE isoform, more Ap appears to accumulate in the early
endosomes, which potentially explains the diminished elimination from the endothelial cells and
transcytosis described in Chapter 2 (Figure 2.5). However, in contrast to the previous studies
investigating the clearance of Ap across the BBB in vitro [179,216], the polarity of the cells in the
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subcellular localisation studies was not assessed. Therefore, it is feasible that changes in directional 
transport and therefore endosomal trafficking may be altered under non-polarised conditions. 
Regardless, changes in internalisation and the early stages of endosomal trafficking were detected which 
may not be significantly influenced by polarisation.
Although these studies provide mechanistic insight into the influence of the apoE4 isoform on A3 transit 
through the BBB, the endosomal trafficking of Ap may be challenging to target pharmacologically. To our 
knowledge, no current therapeutics directly alter the trafficking of proteins through the endosomal 
compartments. Therefore, additional strategies may be required to facilitate the uptake of AP and its 
subsequent clearance across the BBB. The following chapters will investigate the enzymes responsible 
for the ectodomain shedding of LRP1 (Chapter 2) as a potential therapeutic target to facilitate Ap 
elimination from the brain and mitigate the impact of APOE4 on the AD phenotype.
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Chapter 4  : The influence of ADAM10 on LRP1 shedding and clearance of 
Ap across the BBB
4.1 Introduction
As outlined in Chapter 2, the ectodomain shedding of LRP1 and the formation of a soluble LRP1 specifies 
inversely correlates with the clearance of A3 BBB [202]. Thus, reducing brain LRP1 shedding could 
promote Ap clearance across the BBB and attenuate Ap accumulation in the AD brain. As such, 
investigating the factors that regulate LRP1 shedding in the brain may provide therapeutic opportunities 
to lower A3 burden and modulate the AD phenotype. One of the enzymes implicated in LRP1 
ectodomain shedding is the a-secretase, ADAM10 (A Disintegrin And Metalloproteinase domain 
containing protein 10) [146]. The following study will examine the influence of ADAM10 on LRP1 
shedding in vitro and in vivo and evaluate the impact of ADAM10 modulation on A3 clearance across the 
BBB.
The majority of research investigating the involvement of ADAM10 on the pathological mechanisms that 
occur in AD have focused on its function as an a-secretase. In this role, ADAM10 proteolytic activity 
results in the formation of sAPPafrom the amyloid precursor protein (APP) which has been reported to 
exhibit neuroprotective and neurotropic properties (Figure 1.1) [258,259]. Perhaps more importantly, 
ADAM10 also competes with the p-secretase base for cleavage of APP such that an increase in ADAM10 
activity reduces the generation of Ap through the p-secretase mediated amyloidogenic processing of 
APP [260]. The importance of ADAM10 function with regards to APP processing was highlighted by the 
discovery of two rare highly penetrant mutations (Q170H and R181G) that were identified in the 
ADAM10 prodomain that resulted in reduced a-secretase activity [261]. When introduced into models 
of AD over-expressing APP, there was an increase in Ap production in cell culture and an increase the 
brain AP burden in mice [261,262]. However, ADAM10 has a diverse array of substrates that are
involved in the regulation of vascular development and inflammatory [263]. As such, increased ADAM10 
activity is associated with several disease pathologies including atherosclerotic cerebral infarction, 
restenosis and in early tumourigenesis events [264-266]. ADAM10 is also shows proteolytic activity 
against several proteins that are integral for the proper function of the BBB [267,268]. This endothelial 
and tight junction specific activity of ADAM10 suggests that it may be involved in the well documented 
vascular dysfunction that is a common feature of AD [269]. In addition, recent findings linking ADAM10 
activity to the ectodomain shedding of LRP1 further supports this evidence that ADAM10 may be 
involved in the BBB pathologies associated with AD and the clearance of Ap through the BBB.
As previously discussed, APOE4 constitutes the strongest genetic risk factor for AD, with possession of 
one or two APOE4 alleles increasing the chance of developing AD by 4- and 15- fold, respectively, 
compared to APOE3 homozygous individuals [160,162]. However, few studies have assessed the 
potential interaction between apoE and the activity of ADAM10. Of the studies that have assessed this 
interaction, they primarily focus on the non-amyloidogenic processing of amyloid-precursor protein 
(APP) [270]. The A3 induced shedding of LRP1 outlined in Chapter 2 was also found to be apoE 
dependent, indicating that the activity of the protease responsible for the shedding of LRP1 may also be 
influenced by apoE genotype. Therefore, in addition to examining the effect of ADAM10 on LRP1 
shedding, the following studies will also evaluate the interaction between ADAM10 and each apoE 
isoforms.
4.2 Methods
4.2.1 Animals
ADAM10 endothelial KO mice were kindly provided by Dr Carl Blobel (Hospital for Special Surgery, New 
York, NY), Dr B. De Strooper (VIB Centre for the biology of Disease, Leuven, Belgium) and Dr P. Saftig
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(Institute of Biochemistry, CAU Kiel, Germany). These mice were generated by crossing ADAM10 
flox/flox mice [271] with Tie2-Cre transgenic mice that use the endothelial specific promoter Tie2 to 
drive the expression of Cre recombinase [272], which result in ADAM10 flox/flox/Tie2-Cre mice. The 
ADAM10 endothelial KO mice lack ADAM10 expression in the endothelial cells [273]. Wild Type mice on 
a C57BL/6 background were used as control animals. To evaluate the effect of ADAM10 modulation on 
BBB clearance of A3 in an animal model of AD, we utilized transgenic mice overexpressing the human 
APP695 sw mutation and the presenilin-1 mutation M l 46L (PSAPP) which results in the overproduction 
of human A3 [274]. All mice were group housed in a temperature and humidity controlled environment 
on a 12 hour light/dark cycle with free access to food and water. All experiments involving animals were 
approved by the Institutional Animal Care and Use Committee of the Roskamp Institute.
4.2.2 Preparation of Ap42 peptides
Ap42 peptides were prepared in an identical method as previously described in Chapter 2 (section
2.2.3).
4.2.3 Influence of ADAM10 on transit of Ap across an in vitro model of the BBB
The impact of ADAM10 on A342 transcytosis was assessed using an in vitro BBB model previously 
described by our group [216]. HBMECs were seeded onto fibronectin-coated 24-well membrane inserts 
forming a polarised monolayer representing the BBB (Figure 4.1). Ap transcytosis across the BBB was 
assessed by exposing the basolateral side ("brain") to 2pM fluorescein-A342 and treating the apical side 
("blood") with the ADAMlO-selective inhibitor GI254023X (0.1-lpM) (stock solution in DMSO). The 
concentration of DMSO in treatment wells was <0.1%. Previous studies have demonstrated that DMSO 
at these concentrations does not affect the permeability in this BBB model and the conjugation of Ap42 
to fluorescein does not significantly alter the rate of transcytosis of unconjugated A342 through the 
polarised membrane [216]. After 60 minutes of incubation at 37°C, samples were collected from the 
apical compartment to assess the basolateral-to-apical transcytosis of fluorescein-A3 across the BBB. To
ensure the integrity o f the barrier was intact, the basolateral-to-apical permeability o f a paracellular 
marker, lOkDa lucifer yellow dextran, across the BBB model was examined fo r each study. The levels o f 
fluorescein-A(3 in the apical com partm ent were assessed via fluorescence at 485/515 Ex/Em using 
BioTek Synergy HT m icroplate reader.
Apical "blood'' 
compartment
Well insert
Well of 96-well 
plate
Confluent cell 
monolayer
Basolateral "brain' 
compartment
Figure 4.1 Schematic of in vitro BBB model well inserts
4.2.4 Brain LRP1 shedding and Ap BBB clearance in vivo
To determ ine the role o f ADAM10 in the clearance o f Af342 from  the brain to  the periphery, we 
examined the appearance o f human A(342 in the plasma after intracranial adm inistration o f human A(342 
as previously described by our group [216,221]. Briefly, w ild-type and ADAM 10 endothelial KO mice (4 
to  6 months o f age) were anesthetized via inhalation using a 3% isoflurane /  oxygen mix. W hile under 
anaesthesia, vehicle (100% DMSO) or 3pl o f human A|342 (Im M ) was bilaterally injected into the 
caudate putamen o f the brain (0.5mm anterior to  the bregma and 2mm lateral to  the m idline at a depth 
o f 3mm below the skull surface) w ith  approximately 1 m inute between the bilateral injections. Ten
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minutes after the intracerebral injections, the mice were euthanized and the plasma and brain tissue 
were collected. Plasma samples were analyzed for human A342 using an ELISA (Invitrogen Corp., USA). 
Mouse brains were homogenised in 12ml of ice cold Hanks Balances Salt Solution (HBSS) with a Dounce 
Homogenizer. For collection of the soluble brain fraction (i.e., non cell-associated), samples were 
centrifuged at 6000g for 15 minutes to remove cellular debris and non-soluble components. The levels 
of LRP1 in the soluble fraction were measured using a human LRP1 ELISA (Cedar Lane Labs, USA) and 
normalized to the total protein content in the brain homogenate as determined by the bicinchoninic 
acid (BCA) protein assay (Thermo Scientific, USA). Soluble LRP1 levels were expressed as ng of LRP1 per 
mg protein.
4.2.5 Ap and sAPPa levels in PSAPP mice following ADAM10 inhibition 
PSAPP mice at 35 weeks of age were injected intraperitoneally with 200mg/kg of GI254023X or vehicle 
(DMSO) once per day for 5 consecutive days. At this age, PSAPP mice display elevated levels of Ap 
peptides in the brain [274]. This treatment regime has previously been shown to effectively inhibit 
ADAM10 activity in mice and was well tolerated with no adverse effects reported [275]. One hour after 
the final injection, the mice were euthanatized and plasma and brain tissue was collected. The right 
hemisphere was used to examine the levels of soluble and insoluble AP40 and AP42 in the brain. Briefly, 
the hemispheres were homogenized by sonication in 700pl lysis buffer (M-PER + 1%EDTA +0.2%PMSF 
(Thermo Scientific, USA)) supplemented with Halt protease and phosphatase inhibitor cocktail (Thermo 
Scientific, USA) on ice before centrifugation at 14000g for 30 minutes at 4°C. lOOpI of the resulting 
supernatant was mixed with 5M guanidine in TRIS buffer resulting in the guanidine soluble (GS) fraction. 
For the guanidine insoluble (Gl) fraction, lOOpI of the guanidine stock was combined with the original 
tissue pellet. Both GS and Gl fractions were subsequently incubated at room temperature for 1 hour and 
were mixed every 15 minutes. All samples were stored at -80°C prior to analysis. Quantification of A340 
and A342 in the GS, Gl, and plasma fractions was carried out using an ELISA for human Ap40 and Ap42 
(Invitrogen, USA) and expressed as percentage of vehicle control. The left hemisphere was used to
examine the levels of soluble LRP1 in the brain. Here, the hemisphere was homogenized using a Dounce 
homogenizer in ice cold in HBSS using the same procedure as the in vivo LRP1 shedding studies above. 
LRP1 levels in the soluble fraction were assessed by ELISA for mouse LRP1 (Cedar Lane Labs, USA) and 
normalized to the total protein content in the brain homogenate as determined by the BCA protein 
assay (Thermo Scientific, USA). Soluble LRP1 levels were expressed as ng of LRP1 per mg protein. In 
addition, sAPPa levels were examined in the brain homogenate of these same animals using an ELISA for 
sAPPa (IBL international, USA). The sAPPa levels were normalized to the total protein content in the 
brain homogenate as determined by the BCA protein assay and expressed as ng of sAPPa per mg 
protein.
4.2.6 In silico BBB permeability of GI254023X
Values for the prediction of the permeability of GI254023X through the BBB were calculated using 
Molinspiration online resources (www.molinspiration.com). Values obtained were the Octanol-water 
partition coefficient logP (miLogP), topical polar surface area (TPSA in A2), Molecular weight (MW), and 
sum of Oxygen and Nitrogen atoms. Common values in which a compound is considered permeable 
through the BBB are as follows: miLogP - Oxygen and Nitrogen total > 0, TPSA<90 [276] or <60-70 A2 
[277], MW< 400Da [187] to 450Da [278], and the Oxygen and Nitrogen total < 5 [279]. These values 
were used to assess the likelihood of permeability utilising 4 of the rules of thumb outlined by Clarke 
[30]. Additional BBB permeability prediction tests were conducted using resources on 
www.cbligands.org with a SVM algorithm and 4 separate molecular fingerprints. A positive control 
compound, anatabine, which has previously been shown by our group to cross the BBB was assessed 
using the same method to confirm the validity of the tests [221].
4.2.7 Collection and enrichment of human lipidated apoE 
Lipidated apoE was collected as previously described in Chapter 2.2.4.
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4.2.8 ApoE-dependent ADAM10 activity
To assess whether any of the ADAM10 dependent effects are modulated by apoE, we assessed the 
activity of ADAM10 in the presence of the apoE isoforms in a cell-free paradigm. Recombinant ADAM10 
(lpM ) (R&D Systems, Canada) was incubated with lipidated apoE2, apoE3 and apoE4 (0.5-250ng/ml) and 
the fluorescent substrate PEPDAB010 (5nM) (BioZyme Inc., USA) for 1 hour at 37°C. Additionally, the 
kinetic activity of ADAM10 (lpM ) was carried out in the presence of apoE (0.1 - 300ng/ml) and a fixed 
concentration of PEPDAB010 (5nM). In this study, ADAM10 and apoE were preincubated at 37°C for 1 
hour before addition of PEPDAB010. Enzymatic activity was then measured by fluorescence every 35 
seconds for 30 minutes at 37°C. The rate of reaction for each concentration of apoE was calculated by 
taking the initial gradient of the reaction rate in the linear region (fluorescent units/seconds) and 
plotting it against the concentration of apoE. In both the activity and kinetics cell-free assays, to 
determine whether the substrate was metabolised by apoE itself, fluorescent substrate was incubated 
with various concentrations of apoE alone. These values were used as background controls for each 
apoE isoform-ADAMIO treatment combination. For all cell-free activity paradigms, fluorescence was 
measured at 485/528 Ex/Em using a BioTek HT Synergy multidetection microplate reader.
4.2.9 Statistical analysis
Statistical analyses were performed using a one-way ANOVA followed by Tukey's post-hoc analysis 
(GraphPad Prism 5, GraphPad Software Inc., USA). Moreover, where only 2 groups were compared, 
unpaired t-tests were used to evaluate statistical significance. Km values were generated using a 
nonlinear dose-response regression of the data set (Michaelis Menten curve fit). Unless otherwise 
indicated, all n values represent technical replicates.
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4 .3  R e s u lts
4.3.1 Influence of ADAM10 on transit of Ap across an in v itro  BBB model
Previously, we demonstrated tha t inhibition o f ADAM10 w ith  GI254023X reduced the ectodomain 
shedding o f LRP1 (Figure 2.7). Leading on from  these findings, we assessed w hether ADAM10 inhibition, 
and therefore the reduction LRP1 shedding, could increase the transcytosis o f fluorescein-A(342 across in 
an in vitro  BBB model. Treatment o f HBMECs w ith  GI254023X at concentrations increased the 
basolateral to  apical transport o f fluorescein-A(342 in a dose dependent manner (Figure 4.2). Significant 
increases were observed at concentrations higher than lp M  GI254023X showing effects o f 1.25-fold and 
greater. In addition, trea tm ent did not significantly increase the amount o f lOkDa lucifer yellow dextran 
in the apical compartment, suggesting the integrity o f the confluent cell monolayer was not impacted by 
treatm ent.
4.3.2 Brain LRP1 shedding and Ap BBB clearance in vivo
LRP1 levels in the soluble brain fraction o f ADAM10 endothelial KO mice were lower than tha t observed 
in w ild-type animals (
A B
0 8 1 p = 0.06 800-|
ADAM10
endothelial KO WT ADAM10
endothelial KO
Figure 4.3), although this effect did not achieve statistical significance. However, AP clearance across the 
BBB was significantly greater in ADAM10 endothelial KO mice compared to w ild-type animals resulting 
in an increase o f approximately 1.75-fold.
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4.3.3 ADAM10 inhibition in PSAPP mice
To evaluate the impact of ADAM10 inhibition on A3 tissue levels and LRP1 shedding in an AD animal 
model, PSAPP mice were treated with the ADAMlO-selective inhibitor GI254023X. The level of soluble 
LRP1 in the brain was significantly lower in the GI254023X-treated mice compared to the vehicle control 
animals (a reduction of 60%) (Figure 4.4 A). To assess the effect of ADAM10 inhibition on the a- 
secretase cleavage of APP, the levels of sAPPa in the brain were examined following GI254023X 
treatment. No significant difference in the level of sAPPa in the brain was detected between GI254023X- 
treated mice and the control group (Figure 4.4 B). The involvement of ADAM10 in the clearance of A3 
was assessed by measurement of A340 and Ap42 in the plasma and whole brain homogenate.
ADAM10 inhibition significantly increased the levels of A340 in the plasma (1.45-fold) compared to 
vehicle-treated mice, while the effect of GI254023X treatment on plasma A342 showed no significant 
change (Figure 4.5A). In addition, treatment with the ADAM10 inhibitor reduced both soluble and 
insoluble A340 (Figure 4.5B) (1.15- and 1.20-fold respectively) and A342 (Figure 4.5C) (1.20 and 1.25-fold 
respectively) levels in the brain compared to vehicle-treated animals, although these values did not 
reach statistical significance. It should also be noted that this GI254023X treatment regimen was well 
tolerated as the treated animals did not display any overt changes in appearance, behaviour, or weight 
loss.
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Figure 4.2: Fluorescein-A[B42 transit across an in vitro BBB model following ADAM 10 inhibition. 
Fluorescein-Af342 (2pM) was exposed to the basolateral (“ brain") side of the in vitro BBB model, while 
various concentrations of the ADAM10 inhibitor GI254023X (0-10pM) were exposed to the apical 
(“ blood") compartment. Following incubation at 37°C, samples were collected from the basolateral 
compartment at 60 minutes to assess the basolateral-to-apical transcytosis of fluorescein-AP42 across 
the BBB model. Values represent mean ± SEM (n = 3) and are expressed as the percentage change 
from control conditions. *p<0.05; ** p<0.01; * * *  p<0.001 as determined by one-way ANOVA followed 
by Tukey's post-hoc analysis.
4.3.4 In silico  BBB permeability of GI254023X
Prediction o f BBB permeability o f GI254023X was based on the values fo r the miLogP, TPSA, MW  and 
the sum o f Oxygen and Nitrogen atoms. The values obtained fo r GI254023X were as follows: MW  = 
391.51Da (BBB permeable), TPSA = 98.73 A2 (BBB impermeable), sum o f Nitrogen and Oxygen = 7 (BBB 
impermeable), miLogP - (N+O) = -4.4 (BBB impermeable). The additional BBB permeability prediction 
software (cbligands) predicted tha t GI254023X would be permeable in 3 out o f the 4 molecular 
fingerprints. Overall, this suggests tha t GI254023X may have marginal permeability through the BBB.
Our positive control, anatabine which has been previously been demonstrated to  penetrate the BBB was 
predicted to penetrate the BBB in all o f the tests performed [280].
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4.3.5 Cell-free apoE isoform dependent ADAM10 activity
To determ ine the effect o f the apoE isoforms on the activity o f ADAM10, a cell-free activity assay was 
utilised (Figure 4.6A). Following exposure o f apoE isoforms and an ADAM10 fluorescent substrate to 
active recombinant ADAMIO, apoE isoform- and concentration-dependent changes in the activity o f 
ADAM10 were detected w ith  a rank order o f apoE2>apoE3>apoE4. At 25ng/ml apoE, ADAM10 activity 
was significantly lower in the presence o f apoE4 compared to  apoE2 (40% reduction). Although it did not 
reach statistical significance, apoE3 showed consistently higher activity than apoE4 at all concentrations. 
In addition, we also investigated the influence o f apoE isoforms on ADAM10 activity via Michaelis 
Menten kinetics (Figure 4.6B). This revealed tha t apoE2 demonstrated the greatest impact on ADAM10 
activity (EC50 = 0.69ng/ml) fo llowed by apoE3 and apoE4 (EC50 = 16.81ng/ml and 27.17ng/ml, 
respectively)
ADAM10 
endothelial KO ADAM10
endothelial KO
Figure 4.3 : LRP1 shedding in the brain and A(3 clearance across the BBB in ADAM10 endothelial KO 
and wild-type mice. Human AP42 (ImM) was intracranially injected into ADAM10 endothelial KO and 
wild-type mice 10 minutes before collection of the brain and plasma. The soluble fraction of the brain 
was probed for (A) LRP1, while the plasma was probed for (B) A042 using ELISAs. Values represent 
mean ± SEM (n = 9 biological replicates) and are expressed as amount of LRP1 per mg total protein or
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amount of A042 per ml. Statistical analyses were performed using an unpaired t-test compared to the 
wild-type animals.
4 .4  D is c u s s io n
Dysfunction w ith in  the cerebrovascular system is now recognized as a major contribu to ry factor in the 
development o f AD [281-283]. Prior studies have shown tha t reduced levels o f the receptors tha t 
transport AP in brain endothelia, such as LRP1, results in decreased AP clearance across the BBB, 
elevated AP burden in the brain, and aggravated memory and learning deficits [123,282]. Our previous 
works, and the work o f others, shows LRP1 is susceptible to  ectodomain shedding by ADAMIO (Chapter 
2.3.7) [146]. Therefore, in this chapter, we investigate whether inh ib ition o f ADAMIO was a viable 
therapeutic strategy to  facilitate the clearance o f AP by blocking the shedding o f LRP1.
B
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Figure 4.4 : LRP1 shedding and sAPPa levels in the brain following ADAMIO modulation in a mouse 
model of AD. The ADAMIO inhibitor GI254023X (200mg/kg) or vehicle was administered via 
intraperitoneal injection once per day for five consecutive days to PSAPP mice (35 weeks of age). One 
hour after the final injection, the brains were collected and the soluble brain fraction was probed for
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(A) LRP1, while the whole brain homogenate was probed for (B) sAPPa using ELISAs. Values represent 
mean ± SEM (n = 9 biological replicates) and are expressed as the amount of LRP1 or sAPPa per mg of 
total protein. *p<0.05 as determined by an unpaired t-test compared to vehicle control.
Our initial studies found that inhibition of ADAMIO effectively reduced LRP1 shedding and increased AP 
transit across an in vitro model of the BBB. This was supported by our in vivo studies in which ADAMIO 
endothelial KO mice displayed less LRP1 shedding in the brain in conjunction with increased AP 
clearance across the BBB compared to wild-type animals. However, the reductions in the levels of 
soluble LRP1 in the ADAMIO endothelial KO group did not reach statistical significance, although a 
strong trend was observed. This may not be all that unexpected as there are number of cell types in the 
brain that express LRP1 in addition to brain endothelia. As our analytical approach assessed LRP1 levels 
in the entire soluble fraction of the brain, endothelial-specific changes in LRP1 shedding may be difficult 
to capture with so many other cells types contributing to the pool of soluble LRP1. Nevertheless, our 
findings in vitro and in vivo demonstrate that modulation of the ADAMIO enzyme minimizes LRP1 
shedding and facilitates AP clearance across the BBB.
As we identified a role for ADAMIO in mediating Ap clearance across the BBB, we next examined the 
impact of ADAMIO inhibition on AP tissue levels in an animal model of AD. Using an acute 5-day 
treatment paradigm with the ADAMlO-selective inhibitor GI254023X in PSAPP mice, we observed a 
substantial decrease in LRP1 shedding in the brain compared to vehicle-treated animals, which 
coincided with a significant increase in plasma Ap40 levels. We propose that inhibition of ADAMIO 
facilitated Ap40 transit from the brain to the periphery (via reduced LRP1 shedding), resulting in the 
elevated Ap40 plasma levels we observed. However, no significant changes in plasma AP42 levels were 
detected following GI254023X treatment. A potential explanation for the disparity we observed in the 
BBB clearance between Ap40 and Ap42 may be due to differences in the transport rates for these
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species. A recent report indicated LRP1 preferentially clears AP40 over AP42 [123] and prior studies 
have shown that the rate of AP40 transport across the BBB is more than twice that observed for AP42 
[96,284], Nevertheless, the increased levels of Ap40 in the plasma following ADAMIO inhibition suggest 
this treatment strategy may be used to facilitate the transit of Ap from the brain to the periphery.
To examine the impact of ADAMIO inhibition on AP levels in the brain, we examined both guanidine 
soluble and insoluble Ap following GI254023X treatment in PSAPP animals. While we observed 
reductions in both soluble and insoluble AP40 and AP42 in the brain following treatment, none of these 
effects were statistically significant. It is unclear why this treatment paradigm did not modulate AP 
levels in the brain more effectively. Both our prior work [202] and our current findings demonstrate a 
strong relationship between brain LRP1 shedding and Ap clearance across the BBB. In addition, 
although GI254023X treatment in the PSAPP mice reduced LRP1 shedding in the brain by 60%, this effect 
did not translate to significant changes in AP levels in the brain. It may be that such an acute treatment
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Figure 4.5 : A|3 tissue levels following ADAMIO modulation in a mouse model of AD. The ADAMIO 
inhibitor GI254023X (200mg/kg) or vehicle (DMSO) was administered via intraperitoneal injection 
once per day for five consecutive days to PSAPP mice (35 weeks of age). (A)One hour after the final 
injection, the plasma was collected and probed for A(340 and A(342 using an ELISA, while the brain was 
probed for guanidine soluble and insoluble (B) A|340 and (C) A(342, also using an ELISA. Values 
represent mean ± SEM (n = 9 biological replicates) and are expressed as the percentage change from 
vehicle control. Statistical analyses were performed using an unpaired t-test compared to vehicle 
control.
paradigm (5 days) is not sufficient to  demonstrably lower A(3 levels in the brain, and tha t a more chronic
trea tm ent paradigm is necessary. Another possible explanation fo r our observations is tha t LRP1
expression is known to  be lower in AD patients [100,129] and AD animals, including the PSAPP mice
used in the current studies [285]. Exposure o f brain vascular cells to  high levels o f A(3 fo r a prolonged
period has also previously been shown to  reduce the expression o f LRP1 [129]. In our study, the PSAPP
mice were tested at an age when extensive A(3 pathology is present [274,286]. As such, the to ta l LRP1
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population may be depleted to  such an extent tha t any improvements in LRP1 shedding to  promote A3 
elim ination would still prove insufficient. Therefore, this therapeutic approach may be more impactful if 
used earlier in the disease process when a greater density of LRP1 receptors is available fo r therapeutic 
targeting. Therefore, fu rthe r evaluation o f this trea tm ent protocol and the feasib ility o f targeting LRP1 
sheddase enzymes in AD are certainly warranted.
ApoE (ng/ml) AP°E (ng/ml)
Figure 4.6 : Differential modulation of ADAMIO activity by the apoE isoforms. (A) ADAMIO activity in 
a cell-free paradigm was significantly modulated by apoE in an isoform and dose dependent manner 
(apoE2>apoE3>apoE4). Differences between apoE2 and apoE4 were statistically significant at 
concentrations >25ng/ml. For all apoE concentrations, ADAMIO activity was lower in the presence of 
apoE4 compared to the other isoforms. (B) ApoE isoform-specific influence on ADAMIO EC50 values. 
ApoE2 demonstrated the greatest influence on ADAMIO activity (EC50 = 0.69ng/ml ± 0.18) in 
comparison to apoE3 (EC50 = 24.27ng/ml ± 8.04) or apoE4 (52.24ng/ml ± 14.01). Activity data are 
presented as ADAMIO activity (n=3) ± SEM. Statistical significance was determined by two-way 
ANOVA followed by Tukey's post-hoc analysis. EC50 values were generated using a nonlinear 
regression curve with reaction velocity and concentration of apoE (EC50 ± SEM n=3 biological 
replicate). *p<0.05; ** p<0.01; * * *  p<0.001; * * * *  p<0.0001.
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A primary concern in targeting an enzyme like ADAMIO, especially in AD, is the potential impact on 
other substrates that are metabolised by ADAMIO. ADAMIO is one of the a-secretases which processes 
APP through the non-amyloidogenic pathway, resulting in the formation of sAPPa while at the same 
time, precluding the production of Ap peptides. As such, inhibition of this pathway could facilitate A3 
synthesis and potentially exacerbate A3 burden in the AD brain. Our data suggests this is not the case, as 
Ap levels in the brain did not increase upon ADAMIO inhibition, but in fact decreased, albeit modestly.
To ascertain whether GI254023X treatment influenced the a-secretase pathway specifically, we 
measured sAPPa levels in the brain and found no difference between GI254023X-treated animals and 
the vehicle control group. These data indicate ADAMIO can be modulated to reduce LRP1 shedding in 
the brain without affecting the a-secretase cleavage of APP. One explanation for this may be the 
presence of other a-secretase enzymes, which are able process APP when ADAMIO is diminished or 
absent. To this point, it was previously found that sAPPa formation was preserved in fibroblast cells 
derived from ADAMlO-deficient animals [287]. It has also been reported that other members of the a- 
secretase family such as ADAM9 and ADAM17 are able to compensate for reductions in ADAMIO activity 
[287,288]. Alternatively, another report did observe a significant change in sAPPa production in primary 
neurons when ADAMIO was absent, suggesting a lack of compensation by other a-secretases [64]. Data 
from the in silico BBB permeability models suggests that the permeability of GI254023X is marginal, with 
50% of the tests returning a non-BBB permeable prediction. Therefore, it is possible that GI254023X is 
not able to reach neurons, where the majority of APP processing is located, at a high enough 
concentration to influence the non-amyloidogenic processing of APP[289]. Nevertheless, our studies 
demonstrate that targeting the ADAMIO enzyme can effectively reduce LRP1 shedding in the brain 
without impacting APP proteolysis.
In addition to reducing shedding of LRP1 and improving clearance of brain A3, inhibition of ADAMIO at 
the BBB may have additional benefits due to its association with other cerebrovascular related 
pathologies. In particular, increases in ADAMIO expression due to ADAMIO polymorphisms have been
linked with risk factors for AD such as atherosclerotic cerebral infarctions [264]. In addition, ADAMIO is 
also capable of cleaving collagen IV which is a major component of the basement membrane of the 
vasculature [290,291]. A loss of normal collagen function as a result of increased ADAMIO has been 
demonstrated to lead to increased vascular permeability while also reducing transmigration of cells due 
to disruption of E-cadherin function [292,293]. Finally, on a cellular level, cell associated LRP1 has been 
shown to reduce the delivery of apoE to lysosomes, thus preventing apoE degradation [176]. As apoE 
expression inversely correlates with Ap load and therapies directed at increasing its expression have 
shown some success in animal models[180,182], protecting LRP1 at the cell surface may also facilitate 
increased apoE recycling and therefore reduce amyloid levels. In addition, it is also possible that 
inhibition of ADAMIO protects LRP1 from shedding in the periphery and therefore may also facilitate 
increased hepatic clearance of A3 [196].
As APOE genotype is an important factor to consider when investigating the mechanistic pathways that 
may be involved in AD as a result of its strong association with the risk of developing AD, especially with 
the APOE4 genotype. In our study, ADAMIO activity was found to be reduced in the presence of apoE4 
compared to the other apoE isoforms. In addition, we also identified differences in the EC50 of ADAMIO 
by each apoE isoform (apoE2>apoE3>apoE4). Prior work investigating this apoE-ADAMIO interaction 
have primarily focused on the processing of APP through the non-amyloidogenic pathway and, in doing 
so, failed to detect apoE-dependent differences in sAPPa levels in vitro [270]. However, our study 
utilised lipidated apoE, which is likely a better representation of apoE under normal physiological 
conditions than de-lipidated recombinant apoE. Recent studies have indicated that apoE function is 
dependent on the lipidation status of apoE; with poorly lipidated apoE demonstrating different binding 
affinities to A3 while also promoting increased amyloidogenesis in mouse models of AD [168-170]. 
However, the impact of apoE on the activity of ADAMIO (apoE2>apoE3>apoE4) is not consistent with 
the findings in Chapter 2 with regards to the shedding of LRP1 (apoE2<apoE3<apoE4). This suggests that 
the proteolytic shedding of LRP1 by ADAMIO is not influenced by the apoE isoforms. Therefore, the
apoE dependent shedding of LRP1 outlined as in Chapter 2 appears to be driven by another of the 
sheddases. However, while the apoE dependent activity profile of ADAM10 suggests it is not the 
mechanism responsible for the apoE-mediated shedding of LRP1, it may prove to be of particular 
interest with regard to the processing of APP by a-secretases down the non-amyloidogenic pathway. For 
instance, this data suggests that the apoE2 isoform increases the activity of ADAM10 which may result in 
the diversion of more of APP down the non-amyloidogenic pathway and away from Ap production when 
compared to the apoE4 isoform.
In summary, in this chapter we show that modulation of the ADAM10 enzyme can effectively reduce 
LRP1 shedding and promote AP transport out of the brain. After treatment of AD mice with an ADAM10 
inhibitor, we observed increased levels of Ap40 in the plasma, suggesting that BBB clearance of Ap40 
was elevated. However, the reductions witnessed in the levels of brain AP40 and Ap42 failed to reach 
statistical significance. This suggests that a more chronic treatment paradigm may be necessary to 
observe demonstrable changes in Ap brain burden. Nevertheless, while further interrogation of this 
therapeutic approach is necessary, our findings indicate LRP1 sheddases can be targeted to facilitate AP 
elimination through the BBB, providing a novel therapeutic strategy to mitigate Ap accumulation in the 
AD brain. While our findings in the previous chapters indicated an isoform-dependent role for apoE in 
LRP1 shedding and AP-BBB clearance, our observed effects of apoE on the activity of ADAM10 do not 
explain the apoE dependent shedding of LRP1 described in Chapter 2. This suggests that while ADAM10 
is capable of shedding LRP1 and has an impact on the clearance of AP through the BBB, it is not 
responsible for the apoE-mediated shedding of LRP1 outlined in Chapter 2. Therefore, Chapter 5 will 
assess the impact of another sheddase, MMP9, on LRP1 shedding and the clearance of Ap through the 
BBB to further elucidate the mechanisms behind the isoform-specific effects of apoE we observed prior 
Chapters.
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Chapter 5 : The influence of MMP9 on LRP1 shedding and clearance of 
Ap across the BBB
5.1 Introduction
We previously demonstrated that inhibition of the LRP1 sheddase ADAMIO, with the aim of increasing 
the population of cell associated LRP1, is a viable method for increasing the clearance of Ap through the 
BBB (Chapter 4). However, a comparison of the apoE isoform dependent activity profile of ADAMIO 
(Figure 4.6) and the apoE isoform dependent shedding of LRP1 (Figure 2.4) revealed that it may not be 
the main driving factor behind this mechanism. In light of this, we moved our focused to another of the 
LRP1 sheddases, the matrix metalloproteinase 9 (MMP9), in order to assess its impact on the BBB 
clearance of Ap and any interactions it may have with apoE. [147]. The matrix metalloproteinases 
(MMPs) are a family of 28 membrane-bound and secreted calcium-dependent zinc-containing 
endopeptidases. They are involved in a diverse array of processes including the degeneration of the 
extracellular matrix components (ECM), remodelling of tissues, shedding of cell surface markers and 
processing of several signalling molecules in addition to their critical functions in the inflammatory 
response [294]. Due to the multitude of pathways in which they are involved, MMP activity is highly 
regulated at both the transcriptional level and by inhibition by tissue inhibitors of metalloproteinases 
(TIMPs), which bind competitively to their active site [295,296]. However, despite the multiple 
regulatory mechanisms that exist to keep the activity and expression of the MMPs in check [296,297], 
dysfunctional regulation or altered expression of MMPs is implicated in the pathogenesis of several 
neurodegenerative disorders such as AD, Parkinson's Disease and Multiple Sclerosis [298-300].
Of the members of the MMPs family, MMP9 is particularly associated with vascular damage, dysfunction
of the blood-brain barrier (BBB) and AD. Originally termed type IV collagenase or gelatinase B, MMP9 is
synthesised by a diverse array of cells in the central nervous system, such as astroglia, microglia and
neurons [301]. Activation of MMP9 is achieved through a protease cascade initiated by plasmin which
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results in the cleavage of pro-MMP9 to a 82kDa enzymatically active enzyme [302]. MMP9 contains a 
domain unique to this species consisting of three repeats of fibronectin type II which is essential for 
binding to denatured collagen or gelatine [303]. As such, increased MMP9 expression results in tissue 
remodelling and the breakdown of the basement membrane [304,305]. Activation of MMP9 in the 
vasculature is closely linked to the activity of tissue plasminogen activator (tPA), which increases MMP9 
production under hypoxic or ischemic conditions through signalling via the light chain domain of LRP1 
[306,307]. In addition to the studies outlined in Chapter 2, there are also several studies that have 
demonstrated a role of MMP9 in the regulation of LRP1 expression and function [147,229]. These 
suggest that MMP9 has a prominent role in the ectodomain shedding of LRP1 which results in the 
formation of soluble LRP1. Therefore, it is possible that the AD associated cerebrovascular dysfunction 
and defective BBB clearance mechanisms may have MMP9 activity as a common factor. In support of 
this, AD patients were found to have significantly higher MMP9 levels in the plasma when compared to 
control individuals [298]. In addition, exposure of mouse cerebral endothelial cells and rat microvessels 
to AP induced expression of MMP9 and elevated activity [308,309]. Interestingly, there is also some 
evidence to suggest that elevated MMP9 levels in the plasma may be restricted to types of AD that have 
a vascular component, with MMP9 expression significantly higher in the plasma of patients with vascular 
AD when compared to non-vascular AD [310]. In addition to changes in activity and expression of 
MMP9, reduced expression of the endogenous inhibitors TIMP1 and TIMP2 have also been identified 
[311]. This suggest that the endogenous inhibitory mechanisms that help regulated MMP9 activity may 
also be dysfunctional. In support of this, the ratio of MMP9 and TIMP1 in the plasma was found to be a 
strong predictor for differentiating vascular AD from non-vascular AD [312]. Vascular components in 
Alzheimer's disease are common, with approximately 80% of autopsied cases showing deposition of AP 
in the cerebral vessels, termed cerebral amyloid angiopathy (CAA) [308,313]. The presence of CAA is 
associated with both higher expression and activity of MMP9 [308].
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Aside from the vascular associated pathologies linked with MMP9, increased MMP9 activity has also 
been detected in the frontal cortex of AD patients, where it was found to have a strong inverse 
correlation with the Mini Mental State Exam (MMSE) score [314]. This suggests that increased MMP9 
expression or activity may even have a direct deleterious effect on the function of neurons and 
cognition. Similarly, MMP9 null mice demonstrate lower levels of neuronal pathology compared to wild 
type mice after intracerebral haemorrhage as well as reduced microglia and macrophage activation 
[315]. In addition, MMP9 inhibition has been shown to reduce AP induced cognitive deficits and 
neurotoxicity in a mouse model of AD [316].
As previously discussed, APOE4 constitutes the strongest genetic risk factor for AD, with possession of 
one or two APOE4 alleles increasing the chance of developing AD by 4- and 15- fold, respectively when 
compared to APOE3 homozygous individuals [160,162]. The ectodomain shedding of LRP1 outlined in 
Chapter 2, was also found to be apoE isoform dependent, suggesting that the proteases involved in this 
process must be sensitive to the presence of the different apoE isoforms. In Chapter 4, we 
demonstrated that while ADAMIO is capable of causing the shedding of LRP1, it may not be the primary 
driver as its apoE activity profile does not match the apoE mediated shedding demonstrated in Chapter 
2. Therefore, this chapter will investigate if MMP9 is the driver of the apoE isoform-mediated shedding 
of LRP1 and whether blocking MMP9 is a viable therapeutic strategy in AD.
5.2 Methods
5.2.1 Animals
APOE-targeted replacement (APOE-TR) mice (4-6 months of age) were used in this study. These mice are 
from a C57BL/6 background and retain the endogenous regulatory sequences for the physiological 
expression of apoE while expressing the human apoE variants in the absence of the mouse apoE. Mice
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were group housed in a temperature and humidity controlled environment on a 12 hour light/dark cycle 
with free access to food and water. All the experiments involving mice were approved by the 
Institutional Animal Care and Use Committee of the Roskamp Institute.
5.2.2 Preparation of Ap42 peptides
A|342 peptides were prepared in an identical method as previously described in Chapter 2 (section 
2.2.3).
5.2.3 In vitro LRP1 shedding and MMP9 production
Human Brain Microvessel endothelial cells (HBMECs) (ScienCell, USA) were seeded at approximately 
50,000 cells per cm2 into fibronectin-coated 6-well plates [216]. When 90% confluent, cells were treated 
with recombinant MMP9 at 0-250ng/ml (EMD Millipore, USA) to observe shedding of LRP1, or with Ap42 
(0-20pM) to assess any change in MMP9 levels in the media. DMSO concentration was <0.1% in all 
treatment wells. Levels of soluble LRP1 and MMP9 were assessed in the media via LRP1 ELISA (Cedar 
Lane Labs, USA) or MMP9 ELISA (Invitrogen, USA) after the 48 hour incubation period.
5.2.4 Influence of MMP9 on transit of Ap across an in vitro model of the BBB
The impact of MMP9 on A(342 transcytosis was assessed using an in vitro BBB model previously 
described by our group [216]. HBMECs were seeded onto fibronectin-coated 24-well membrane inserts 
forming a polarised monolayer representing the BBB. AP transcytosis across the BBB was assessed by 
exposing the basolateral side ("brain") to 2pM fluorescein-Ap42 and treating the apical side ("blood") 
with the MMP9-selective inhibitor SB-3CT (0.1-10pM). The levels of DMSO were kept under 
concentrations previously shown to have no effect on the integrity of the membrane [216]. After 60 
minutes of incubation at 37°C, samples were collected from the apical compartment to assess the 
basolateral-to-apical transcytosis of fluorescein-AP across the BBB model. To ensure the integrity of the 
barrier was intact, the basolateral-to-apical permeability of a paracellular marker, lOkDa lucifer yellow 
dextran, across the BBB model was examined for each study. The levels of fluorescein-AP in the apical
compartment were assessed via fluorescence at 485/515 Ex/Em using BioTek Synergy HT microplate 
reader.
5.2.5 Collection and enrichment of human lipidated apoE
Lipidated apoE was collected as previously described in Chapter 2 (section 2.2.4).
5.2.6 Impact of apoE isoforms on MMP9 activity
The effect of apoE isoforms on MMP9 activity was assessed in a cell-free paradigm utilising a fluorescent 
substrate as per the manufacturers' instructions (Anaspec, USA). Briefly, recombinant MMP9 (5nM) was 
incubated in the presence of lipidated apoE2,3 and 4 (0-250ng/ml) and the fluorescent substrate for 1 
hour at 37°C before detection of fluorescence. To determine whether the substrate was metabolised by 
apoE itself, fluorescent substrate was incubated with various concentrations of apoE alone in the 
absence of MMP9. These values were used as background controls for each apoE isoform-MMP9 
treatment combination. Fluorescence was measured at 340/490 Ex/Em using BioTek Synergy HT 
microplate reader.
5.2.7 ApoE isoform dependent shedding of LRP1 by MMP9 in isolated APOE-TR mouse 
cerebrovasculature
The cerebrovascular fractions were isolated from APOE-TR mouse cortices using a technique previously 
described by our group [202]. Briefly, using a Dounce homogenizer, the tissue was homogenized in HBSS 
on ice. The homogenized tissue was diluted 1:1 with 40% dextran followed by centrifugation at 6000g 
for 15 minutes at 4°C. The soluble fraction and parenchymal pellets were discarded leaving the 
remaining cerebrovasculature. These were treated with MMP9 (0-250ng/ml) for 3 hours at 37°C and the 
extracellular solution probed for soluble LRP1 using an LRP1 ELISA (Cedar Lane Labs, USA).
Unfortunately, due to limited numbers and difficulties in mouse breeding (personal communications 
LaDu), only APOE2 and APOE4 mice were available for use in this study.
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5.2.8 Inhibition of MMP9 and LRP1 shedding in vivo
APOE-TR mice were administered vehicle (25% DMSO, 65% PEG400,10% water) or the MMP9 selective 
inhibitor, SB-3CT (25mg/kg) via intraperitoneal injection. This dose has previously been demonstrated to 
effectively attenuate MMP9 function [305,309,317]. 45 minutes after the i.p. injection, the mice were 
intracranially injected with human Ap42. Ten minutes after the AfS42 injection, the mice were 
euthanatized and the plasma and brain were collected. Soluble brain fractions were isolated from 
mouse whole cortex samples using a technique as previously described [202]. The parenchymal 
cerebrovascular pellets were discarded and the levels of soluble LRP1 were measured in the soluble 
fraction by LRP1 ELISA (Cedar Lane Labs, USA). Additionally, the levels of the intracranially injected 
human A|342 was measured in the plasma by ELISA (Invitrogen, USA). Unfortunately, due to difficulties in 
mouse breeding (personal communications LaDu), only APOE3 and APOE4 mice were available for use in 
this study.
5.2.9 Statistical Analysis
Statistical analyses were performed using a one-or two-way ANOVA followed byTukey's post-hoc 
analysis (GraphPad Prism 5, GraphPad Software Inc., USA). Unless otherwise indicated, all n values 
represent technical replicates.
5.3 Results
5.3.1 MMP9 induces shedding of LRP1 in vitro
To assess whether MMP9 is capable of inducing shedding of LRP1 in vitro, we exposed HBMECs to 
increasing concentrations of MMP9 for 48 hours (Figure 5.1A). Both lOOng/ml and 250ng/ml MMP9 
significantly increased the shedding of LRP1 as detected in the cell culture media. The highest of these 
concentrations increased the levels of soluble LRP1 by 2-fold.
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5.3.2 MMP9 release is induced by Ap in HBMECs
Exposure of HBMECs to A342 for 48 hours demonstrated a significant increase in the expression of 
MMP9 in a dose dependent manner (Figure 5.IB). Treatment of HBMECs with concentrations higher 
than lOpM Ap42 increased the expression of extracellular MMP9 in the media by at least 6-fold when 
compared to the control.
5.3.3 Influence of MMP9 on transit of Ap across an in vitro model of the BBB
The transit of fluorescein-Ap42 across an in vitro model of the BBB was increased by inhibition of MMP9 
(Figure 5.2). A dose dependent increase in the basolateral to apical transport of fluorescein-AP was 
observed with the MMP9 inhibitor SB3-CT with greatest increase in BBB transit at the highest 
concentration (2-fold increase at lOpM). In addition, treatment did not significantly increase the amount 
of lOkDa lucifer yellow dextran in the apical compartment, suggesting the integrity of the confluent cell 
monolayer was not impacted by treatment.
5.3.4 ApoE dependent MMP9 activity
The activity of MMP9, as measured by cleavage of fluorescent substrate, was inhibited in a dose and 
apoE isoform manner (apoE2>apoE3>apoE4) (Figure 5.3). At 25ng/ml apoE, both apoE2 and apoE3 
significantly reduced the cleavage of the substrate to approximately 70 and 80% of the control 
respectively. Inhibition was greatest that the highest dose of apoE (250ng/ml) where apoE2, apoE3 and 
apoE4 significantly reduced cleavage of the MMP9 substrate to 20, 30 and 50% of the control.
5.3.5 ApoE dependent shedding of LRP1 in an ex vivo cerebrovascular preparation
In order to assess the influence of MMP9 on the shedding of LRP1 in an apoE environment, MMP9- 
mediated shedding of LRP1 was assessed in an ex vivo preparation of the cerebrovasculature from 
APOE-TR mice (Figure 5.4). Levels of soluble LRP1 were highest in the vasculature from APOE4 after 
MMP9 treatment, with the vasculature from APOE2 mice showing the lowest levels. Both genotypes 
demonstrated higher levels of soluble LRP1 with MMP9 treatment compared to untreated controls.
5.3.5 In  v ivo  shedding of LRP1 and BBB clearance of Ap in APOE-TR mice 
To assess the impact o f MMP9 on the shedding o f LRP1 in vivo, MMP9 activity was inhibited using an 
acute SB-3CT trea tm ent paradigm (Figure 5.5A). This resulted in a significant reduction in the levels o f 
soluble LRP1 in the APOE4 mice (>50% reduction). In addition, clearance o f AP through the BBB in the 
SB-3CT treated APOE4 mice was significantly higher than in the APOE4 naive mice (Figure 5.5B). The BBB 
clearance o f Ap in the treated APOE4 mice reached a level comparable to  tha t seen in the untreated 
APOE3 mice.
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Figure 5.1: The influence of MMP9 on the shedding of LRP1 in HBMECs. (A) HBMEC monolayers were 
exposed to active MMP9 (0-250ng/ml) for 48 hours at 37°C. LRP1 shedding was assessed by 
examining LRP1 content in the extracellular media using an LRP1 ELISA. (B) MMP9 levels were 
increased in the media of HBMECs after treatment with AP42 (0-20pM) in a dose dependent manner. 
MMP9 levels were assessed by examining MMP9 content in the extracellular media using an MMP9 
ELISA. Values represent mean ± SEM (n = 3) and are expressed as ng of extracellular protein per ml of 
media. *p < 0.05; ****p<0.0001 as determined by one-way ANOVA followed by Tukey's post-hoc 
analysis.
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Figure 5.2 : Fluorescein-Ap42 transit across an in vitro BBB model following MMP9 inhibition. 
Fluorescein-Ap42 (2pM) was exposed to the basolateral ("brain") side of the in vitro BBB model, while 
various concentrations of the MMP9 inhibitor SB3-CT (0-10pM) were exposed to the apical ("blood") 
compartment. Following incubation at 37°C, samples were collected from the apical compartment at 
60 minutes to assess the basolateral-to-apical transcytosis of fluorescein-AP42 across the BBB model. 
Values represent mean ± SEM (n = 4) and are expressed as the percentage change from control 
conditions. *p<0.05 as determined by one-way ANOVA followed by Tukey's post-hoc analysis.
5 .4  D is c u s s io n
Dysfunctional regulation of MMP9 in AD has been shown to  have m ultip le  implications in both vascular 
and neurological health as a result o f the diverse array o f processes in which it is involved. For example, 
high levels o f MMP9 is associated w ith  hypoxic or ischemic conditions, reduced performance in cognitive 
tests and breakdown of basement membranes [298,304-307,314]. There are also indications tha t 
MMP9 may be involved in pre-clinical AD, w ith  increased expression o f MMP9 detected in the CSF of 
healthy individuals who have an AD-supportive CSF biomarker pattern [318,319].
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Figure 5.3 Differential modulation of MMP9 activity by the apoE isoforms. MMP9 activity was 
significantly modulated by apoE in an isoform and dose dependent manner (apoE2>apoE3>apoE4). 
Differences between apoE2 and apoE4 were statistically significant at concentrations >25ng/ml. 
Values represent mean ±SEM (n = 3) and are expressed as fluorescent units. Statistical significance 
was determined by two-way ANOVA followed by Tukey's post-hoc analysis. * * * *  p<0.0001; $p<0.05 
compared to the lowest dose of apoE.
Although the precise cause and trigger o f this altered MMP9 activity is unknown, it is clear that 
strategies targeting MMP9 may be beneficial on m ultiple fronts w ith  regards to  AD pathology. The 
current study sought to  elucidate the MMP9 driven mechanisms tha t may contribute to  the effect o f 
apoE on the clearance o f A(3 through the BBB as described in Chapter 2. Initially, we confirmed the 
ability o f MMP9 to cleave the fu ll length LRP1 in HBMECs. Interestingly, the levels o f MMP9 tha t induce 
shedding o f LRP1 in both our in vitro  and ex vivo studies are similar to  the levels witnessed in the plasma 
o f AD patients [298]. The direct involvement o f MMP9 in the clearance o f A(3 was demonstrated in an in 
vitro  BBB model w ith  increasing concentrations of MMP9-selective inh ib ito r improving the transcytosis 
o f A(3 across a polarised membrane. We also demonstrated tha t the expression o f MMP9 itself can be
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Figure 5.4 Shedding of LRP1 by MMP9 in an ex vivo preparation of APOE-TR mouse 
cerebrovasculature. Induction of LRP1 shedding by MMP9 (0-250ng/ml) in the APOE-TR mouse 
cerebrovasculature increased soluble LRP1 in an APOE dependent manner (APOE2<APOE4). MMP9 
increased the levels of soluble LRP1 in all genotypes with APOE4 mice demonstrating the largest 
increase between control and MMP9 treated at lOOng/ml MMP9. Values represent mean ±SEM (n = 4 
biological replicates) and are expressed as ng of LRP1 protein per ml. ****p<0.0001 as determined by 
two-way ANOVA followed by Tukey's post hoc analysis.
induced in endothelial cells by exposure to  A|3, an im portant factor to  consider w ith  regards to  AD and 
the amyloid cascade. We hypothesise tha t there be a may feed-forward mechanism, whereby 
expression o f MMP9 is increased due to  the high levels o f A(3, resulting in reduced clearance o f A(3 and 
therefore, more stimulus fo r MMP9 release. The activity o f MMP9 is also dependent on the apoE 
isoform present. While all apoE isoforms demonstrated inh ib itory-like behaviour towards MMP9, apoE4 
demonstrated significantly lower ability to  inh ib it activity compared to  the other apoE isoforms. The lack 
o f inh ib ition o f MMP9 in the presence o f apoE4 may be the mechanism responsible fo r the increased 
shedding o f LRP1 and the lowered BBB clearance o f A(3 as demonstrated in the APOE4-TR mice (Chapter
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Figure 5.5 The influence of MMP9 on LRP1 shedding and AP clearance through the BBB in APOE-TR 
mice. (A) Treatment of APOE4 mice with the MMP9 inhibitor SB-3CT (25mg/kg) reduced the shedding 
of LRP1 and (B) increased the clearance of Ap through the BBB, reaching approximately the same 
levels as those in naive APOE3 mice. Values represent mean ±SEM (n = 4 biological replicates) and are 
expressed as ng of LRP1 protein per ml or % control Ap42 in plasma. *p<0.05, ****p<0.0001 
asdetermined by one-way ANOVA followed by Tukey's post hoc analysis or Student's t-test.
2). As LRP1 is the most efficient transporter of AP when compared to other members of the lipoprotein 
group, it seems plausible that this reduction in transport occurs as a result of the increased MMP9 
mediated shedding of LRP1 in the APOE4 mice and not through changes in other lipoprotein receptor 
function [131]. The apoE isoform effect was also witnessed ex vivo, with the cerebrovasculature from 
APOE2 mice showing significantly less LRP1 shedding than APOE4 cerebrovasculature after MMP9 
challenge. Interestingly, the level of AP BBB clearance in the APOE4 treated mice was approximately the 
same as those observed in naive APOE3 mice. These findings suggest MMP9 inhibition can overcome the 
inefficiency of the apoE4 isoform and can facilitate AP BBB clearance to such a degree that it reaches 
levels comparable to that observed for the APOE3 genotype.
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To date, there has been little investigation into the relationship between the apoE isoforms and MMP9. 
However, a recent study observed that the apoE2 and apoE3 isoforms reduce the levels of inflammatory 
molecules which are associated with the activation of MMP9, whereas apoE4 showed little effect. In 
addition, these effects were found to be mediated through LRP1 signalling [309]. Later studies by the 
same group identified that reductions of LRP1 in endothelial cells and pericytes was associated with an 
increased expression of MMP9 in APOE3 and APOE4 individuals with AD when compared to controls 
[320]. In combination, these findings, and those from this study, strongly implicate MMP9 in the 
mechanisms that drive the APOE dependent risk factors for AD. In addition, it appears that the impact of 
MMP9 is multifaceted, seemingly directly altering activity and also altering signalling the cascades 
through LRP1.
While there have been some reports outlining the beneficial aspects of MMP9 in AD, namely its ability 
to degrade AP plaques as well as Ap monomers [321], pathological expression of MMP9 results in both 
structural and functional damage to the cerebrovasculature and BBB clearance mechanisms. It has now 
been demonstrated that aggregated Ap plaques do not correlate well with the neuronal apoptosis and 
synaptic dysfunction seen in AD and that the soluble oligomeric species are the main driver of Ap 
toxicity [20,25,26]. Therefore, the ability of MMP9 to degrade plaques, which was previously identified 
as a potential benefit with regards to AD pathology, may be inconsequential to the symptomatology of 
AD. In addition, MMP9 mediated degradation of the AP40 and AP42 monomers is significantly less 
efficient than other MMP species, and is therefore probably not the primary proteolytic enzyme 
involved in this process [322]. This suggests that increasing the expression of MMP9 with the aim of 
degrading Ap is ineffectual, and therefore probably has little positive effect. Furthermore, the inhibition 
of MMP9 activity in AD patients may have several beneficial outcomes in addition to improving the 
LRPl-mediated transport of AP through the BBB as outlined in this study. For example, it has been 
demonstrated that inhibiting MMP9 reduces Ap-induced cognitive deficits and neurotoxicity in mouse 
models [316,323], lowers microglial activation [315], and can protect the vasculature and BBB tight
junctions from damage and degradation [309,317,324]. In addition, proteolysis of tau by MMP9 
facilitates the formation of tau oligomers and increases aggregation whereas cleavage by other 
members of the MMP family appears to occur in sequences that are required for fibril formation [325]. 
Therefore, MMP9 inhibition may also reduce AD-related tau pathology.
Previously, the inhibition of MMPs as a therapeutic target has been hampered by dose-limiting toxicity 
and insufficient clinical benefit, probably as a result of the diverse roles of in which MMPs play in cellular 
homeostasis [326-328]. However, selective targeting of MMP9 in rats using antibody based approaches 
has been shown to inhibit its activity and resulted in none of the musculoskeletal pathologies that are 
associated with broad spectrum inhibition of MMPs [329,330]. Nonetheless, questions still arise 
regarding the effect of the inhibition MMP9 on memory function and neurogenesis. It has previously 
been demonstrated that MMP9 function is required for the completion of LTP, with genetic and 
pharmacological blockage of MMP9 function in mice causing deficits in long term potentiation and 
hippocampal-dependent memory tasks which could be completely reversed with administration of 
active MMP9 [331,332]. In contrast, blockade of MMP9 has also been demonstrated to improve the 
memory deficits associated with A3 [316]. Therefore, inhibition of MMP9 may still prove to be 
particularly beneficial in an AD environment with high levels of A3-
In summary, the data outlined in this chapter suggests that the apoE dependent clearance of A3 through 
the BBB may be due to a direct inhibitory interaction of apoE on MMP9 activity. In addition, the 
increased levels of MMP9 detected in AD may be the result of A3 driven expression of MMP9 in several 
cell types, including endothelial cells. This chapter builds on the previously established pathological 
mechanisms of MMP9 in AD by adding a potential MMP9 dependent and apoE modulated mechanism 
that increases LRP1 shedding and lowers A3 clearance through the BBB. It has recently become possible 
to target MMP9 selectively, thereby opening the door to inhibition of MMP9 as a potential therapeutic 
target. The ability of this approach to be beneficial in multiple areas of AD pathology, including the
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facilitation of BBB clearance of A3 as outlined in this chapter, makes it an attractive target that certainly 
warrants further investigation.
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Chapter 6 : Discussion and conclusions
6.1 Overview
Alzheimer's disease (AD) is a neurodegenerative disease characterised by a progressive cognitive 
decline. While deficits in short term memory are often the initial symptoms reported, as the disease 
progresses, problems with language, loss of motivation, changes in behaviour and disorientation also 
occur. The clinical diagnosis of AD relies on a battery of tests including the Mini-Mental Status Exam 
(MMSE), neurological, psychiatric examinations, medical history, and recently developed neuroimaging 
techniques [7]. However, definitive confirmation of an AD diagnosis still relies on post-mortem 
pathological analyses based on the localisation of extracellular Ap plaques and NFTs in the 
hippocampus, amygdala, cerebral cortex [8,9].
Patients who develop AD have an average life expectancy of 7 to 10 years after diagnosis [333]. The 
current therapeutic strategies are only palliative and, at best, produce only temporary mild benefits to 
cognition. As a result prevalence and incidence projections for AD indicate that the number of cases will 
continue to grow, with 7.7 million new cases every year [334]. The greatest increases are expected to 
occur in developing countries as a result of their fast growing elderly populations. According to the 
world health organisation, the total number of people affected by dementias worldwide, of which AD is 
the most common form, is expected to double every 20 years and reach approximately 115 million 
individuals by 2050. In addition, it has been estimated that by 2050, 22% of the world population will be 
over 60 and at high risk of developing AD. Currently, the cost of treating and caring for patients with 
dementias worldwide is proposed to be at least £450 billion and is expected to rise in line with the 
increasing prevalence. For example, in Europe, the cost of dementia treatment is expected to rise by as 
much as 43% between 2008 and 2030 [335]. This increasing economic and social burden as a result of 
AD is further compounded by the lack of an immediate solution. Therefore, a better understanding of
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the processes involved in the aetiology and pathology of AD is essential if the huge burden of this 
disease is to be addressed through the development of novel therapeutic strategies.
One of the most widely accepted theories put forth to explain the underlying pathology of AD is the 
amyloid cascade hypothesis. This hypothesis posits that the deposition of Ap in the brain is a crucial step 
leading to the development of AD and the associated progressive cognitive decline. While this 
hypothesis has been altered many times since its inception, the current consensus is that soluble Ap 
species are the main pathological driver for AD [336]. The accumulation of soluble AP species has been 
found to strongly correlate with the extent of neurodegeneration as well as the severity of the cognitive 
symptoms of AD [3,4]. Blocking production of AP has historically been a popular strategy for therapeutic 
intervention in AD. The primary targets for this approach are the p- and y-secretases which produce Ap 
through the processing of APP through the amyloidogenic pathway. However, developing viable 
therapeutics for AD through the pharmacological modulation these enzymes has proved challenging, 
with clinical trials either failing to reach their clinical endpoint or being aborted due to adverse reactions 
[40-42,337]. Regardless, the feasibility of this approach as a therapeutic avenue for AD will be further 
informed after the completion several BACE inhibitor clinical trials over the next few years [338,339]. 
Similarly, other approaches, such as the active and passive antibody based approaches which aim to 
either stimulate production of anti-AP antibodies in the periphery or increase the uptake of Ap into 
phagocytic cells, have also met with mixed or disappointing results as well as considerable side effects 
[52,53,55,56,340]. With the high failure rate of AD clinical trials and the enormous projected increase in 
cases of AD in the future, there is a desperate need for effective disease modifying therapeutics that 
have the capacity to prevent, or at the very least, slow disease progression [12]. In light of this, the 
pursuit of new avenues of therapeutic intervention is of the utmost importance if the worldwide burden 
is to be alleviated.
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There is mounting evidence that the accumulation of Ap in the brain is not due to an increase in AP 
production, but rather a reduced capacity to eliminate AP from the brain [75,177]. More specifically, the 
neurovascular hypothesis of AD proposes that the accumulation of Ap in the brain and the resulting AP 
pathology occurs as a result of dysfunctional clearance mechanisms for Ap through the BBB [341]. 
Interestingly, these AP BBB clearance mechanisms appear to be dependent on the apoE isoforms, 
suggesting that this interaction may be one of the factors that increases the risk of developing AD in 
individuals with an APOE4 allele [177,179]. In this study, we have proposed several mechanisms to 
describe our observed effects of apoE on the clearance of AP through the BBB. The purpose of this 
thesis was to interrogate the potential mechanisms involved in this interaction and to identify areas in 
which this process could be leveraged to restore the clearance of Ap through the BBB and therefore 
mitigate the accumulation in of AP brain.
6.2 Summary of findings
Clearance of AP through the BBB requires the uptake and the subsequent transcytosis of AP through the 
cerebrovasculature. This involves the rapid initial internalisation of AP as well as efficient trafficking 
through the endosomal compartments. Approximately 25% of AP clearance from the brain is attributed 
to clearance through the BBB which, according to the neurovascular hypothesis, is reduced in AD and 
leads to an increased accumulation of AP in the brain [75,101,123].
One of the main receptors responsible for uptake and subsequent clearance of Ap through the BBB is
the low density lipoprotein receptor-related protein 1 (LRP1). Endothelial specific knockout of LRP1 in
mice was found to significantly reduce the clearance of AP through the BBB leading to increased soluble
Ap in the brain, and deficits in memory and spatial learning [123]. The LRP1 receptor is susceptible to
ectodomain shedding, which results in the production of a transmembrane fragment and a soluble LRP1
protein. This soluble LRP1 maintains its ability to bind ligands but lacks the ability to internalise and
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transcytose ligands through the cell [342]. This shedding process can be induced by exposure to AP 
although the precise mechanisms by which the shedding of LRP1 occurs as a result of exposure to AP 
remain unknown.
Our study identified an apoE dependent effect on the Ap-induced shedding of LRP1 where the apoE2 
and apoE3 isoforms were more effective than the apoE4 isoform at protecting the ectodomain shedding 
of LRP1. We also observed APOE allele dependent transport of AP through the BBB in mice, which was 
inversely correlated with the levels of soluble LRP1, suggesting that shedding of LRP1 may negatively 
impact the BBB clearance of Ap. In addition, we identified APOE dependent expression of LRP1 in the 
brain and cerebrovasculature in human samples, with non-demented samples displaying increased 
expression when compared to AD samples. Interestingly, the ND APOE4 samples displayed the highest 
LRP1 expression, suggesting that this increase in expression may be compensating for the risk factor 
associated with the APOE4 genotype.
The clearance of Ap through the BBB is a multistage process which is also dependent on the efficient 
trafficking of AP through the endosomal compartments after the initial internalisation. Therefore, we 
investigated whether the uptake of AP and endosomal trafficking of AP was altered as a result of the 
different apoE isoforms. We observed an increase in Ap internalisation in cells exposed to apoE4 which, 
at first, appears to contradict the findings in Chapter 2 where APOE4 mice demonstrated reduced 
clearance through the BBB. However, the endosomal trafficking of AP in HBMECs also appears to be 
influenced by the apoE genotype present. It has previously been established that the endosomal 
transport of proteins, and the endosomes themselves, are dysfunctional in AD, with an increase of early 
endosome number and size [250,252]. It has also been suggested that dysfunction of the endosomal 
system could be one of the earliest detectable pathologies associated with AD and may therefore be 
one of the driving pathologies [250]. However, this defective trafficking in endosomes has also been 
identified in the brains of Down's Syndrome patients, a disease which is also associated with an increase
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of AP in the brain [250,251,343]. This suggests that altered endosomal trafficking may occur as a result 
of the high levels of AP, indicating that dysfunctional protein trafficking may be a secondary pathology in 
both AD and Down's syndrome and not the primary cause. Regardless, our studies suggest that this 
dysfunction may be exacerbated by the apoE isoforms, with Ap and apoE4 in combination causing an 
increase in the number and size of early endosomes in brain endothelial cultures. Interestingly, these 
enlarged early endosomes have previously been identified in AD brains and can be induced 
experimentally by disruption of downstream endosomal compartments, resulting in accumulation of Ap 
in the early endosomes [250,254]. In contrast, cells exposed to the apoE2 isoform had fewer and smaller 
early endosomes. In comparison, we observed no apoE dependent effect on the recycling endosomes. 
Therefore, we conclude that while the apoE2 treated cells may endocytose Ap at a slower rate than the 
apoE4 treated cells, the absence of swollen early endosomes, which are indicative of AP accumulation 
and dysfunctional trafficking mechanisms, suggests apoE2 must be more efficient at directing Ap to the 
luminal surface of the cells, thus resulting in an increase in AP transported across the BBB.
Although the intracellular trafficking of AP in the cerebrovasculature appears to be apoE dependent, and
modulation of these mechanisms could feasibly increase clearance of AP through the BBB,
pharmacological targeting of these processes may prove challenging as a result of the ubiquitous nature
of intracellular trafficking in all cell types. In addition, as previously discussed, the dysfunctional
endosomal trafficking may only be a secondary pathology, which occurs as a result of a high Ap burden.
As such, the use of this therapeutic approach with the aim of slowing or even halting the progression of
AD may be limited. In light of this, increasing the initial internalisation of AP at the BBB through
increasing the expression of LRP1 may be a more attractive target to facilitate the clearance of AP
through the BBB. While increasing the expression of LRP1 through stimulating its transcription would
appear to be the most obvious approach, this avenue of intervention has previously proven challenging
due to a narrow therapeutic window [344]. Therefore, we propose that inhibition of the sheddases
responsible for the ectodomain shedding of LRP1 may be a more viable approach to maintain a
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sufficient population of functional LRP1, thus enabling the clearance of AP across the BBB. We identified 
several prospective proteases which regulate the shedding of LRP1 in HBMECs, including the a-secretase 
ADAMIO and the matrix metalloproteinase MMP9, and assessed whether inhibition of these proteases 
was a viable therapeutic approach to facilitate the clearance of AP through the BBB. In addition, due to 
the large influence that the apoE isoforms have on risk of developing AD and the previously described 
clearance of Ap through the BBB, we also assessed whether the activities of these sheddases were 
influenced by the different apoE isoforms.
ADAMIO is believed to be the main constitutive a-secretase which is responsible for the initial step in 
the non-amyloidogenic processing of the amyloid precursor protein (APP) in the brain [63,64]. However, 
it has previously been found to have enzymatic activity against LRP1 [146]. Initially we investigated 
whether inhibition of ADAMIO reduced Ap induced shedding of LRP1 and could therefore be used to 
increase the increase the LRP1 dependent transport of Ap across the BBB. We demonstrated that 
inhibition of ADAMIO reduced the shedding of LRP1 and increased the clearance of AP through the BBB 
in both in vitro and in vivo paradigms. However, a primary concern in the use of an ADAMIO inhibitor, 
particularly for the treatment of AD, is the effect it may have on the processing of APP as inhibition of 
the a-secretase non-amyloidogenic pathways could feasibly result in diversion of APP down the 
amyloidogenic pathway and the increased production of Ap. Interestingly, treatment did not 
significantly impact the processing of APP down the non-amyloidogenic pathway, suggesting that either 
the a-secretase activity was compensated for by other members of the family, or that the inhibitor was 
not reaching the site of APP processing at high enough concentrations to have an impact. In addition, 
the newer generation of ADAM10/17 inhibitors have shown no signs of side effects that were previously 
associated with the inhibition of ADAMIO or ADAM17, suggesting that this may be a viable and 
relatively safe avenue of therapeutic intervention [266,345].
Page | 120
However, there are indications that the ADAMIO mediated shedding of LRP1 is apoE independent 
suggesting that it may not sheddase responsible for the apoE dependent levels of soluble LRP1. For 
example, cell-free activity assays demonstrated that apoE2 facilitated the cleavage of a fluorescent 
substrate to a greater degree when compared to the apoE3 and apoE4 isoforms. This activity profile is in 
contrast to the apoE mediated shedding of LRP1 outlined in Chapter 2, where the apoE2 isoform 
protected LRP1 from shedding. If ADAMIO was the primary driver of LRP1 shedding in the 
cerebrovasculature, we would witness an increase in the shedding of LRP1 as a result of apoE2. As this 
does not appear to be the case, we must conclude that while ADAMIO is capable of inducing the 
shedding of LRP1, it must not be the main driver of the apoE dependent mechanism for LRP1 clearance 
of AP through the BBB. However, while this ADAMlO-apoE interaction may not be involved in this 
process, it may prove to be of particular interest with regard to the processing of APP by ct-secretases 
down the non-amyloidogenic pathway. For instance, these data suggest that the apoE2 isoform 
increases the activity of ADAMIO which may result in increased processing of APP through the non- 
amyloidogenic pathway and less AP production when compared to the apoE4 isoform. Regardless, 
while it is clear that ADAMIO is capable of inducing LRP1 shedding, it did not appear to be the relevant 
sheddase responsible for in the apoE-dependent shedding of LRP1 at the cerebrovasculature. Therefore, 
we assessed the interaction between another sheddase, MMP9, and the apoE isoforms with regards to 
the shedding of LRP1.
Multiple pathologies in AD are associated with an increase in the expression of MMP9 [298,310,314]. As 
such, inhibition of MMP9 may be beneficial on many fronts, with existing studies demonstrating its 
ability to ameliorate AP-induced cognitive deficits and neurotoxicity [316,323], lower microglial 
activation [315], and protect the BBB from degradation [309,317,324]. However, little investigation has 
been done into MMP9 within the scope of apoE mediated pathology. To assess whether MMP9 is the 
pathological driver in the apoE dependent shedding of LRP1, we selectively inhibited MMP9 in vitro. This 
resulted in a significant reduction in the levels of soluble LRP1, suggesting that the modulation of MMP9
may be a viable target to increase the clearance of Ap through the BBB by blocking LRP1 shedding. In 
contrast to the apoE-ADAMIO activity profile, MMP9 was inhibited by the apoE isoforms, albeit to 
varying degrees. In this paradigm, apoE2 demonstrated the highest levels of inhibition and apoE4the 
lowest. This apoE isoform-dependent activity profile was in agreement with the pattern of apoE- 
mediated shedding of LRP1 outlined in Chapter 2, suggesting that MMP9 may be the pathological driver 
for the apoE-mediated shedding of LRP1 in the brain, thus, the cause of the reduced clearance of AP 
through the BBB witnessed in our study.
In support of this, inhibition of MMP9 increased the transport of AP through the BBB in an in vitro BBB 
model, leading us to advance these findings into an in vivo model. Previously, have demonstrated that 
APOE4 mice, following intracranial administration of exogenous Ap, demonstrated significantly lower 
levels of Ap in the plasma when compared to APOE3 mice. However, after treatment of APOE4 mice 
with an MMP9 inhibitor, APOE4 mice had comparable levels of Ap in the plasma as untreated APOE3 
mice, indicating an increase in the BBB clearance of Ap. This suggests that blocking the shedding of LRP1 
via MMP9 inhibition may be of particular use in individuals with the APOE4 allele who have increased 
risk of developing AD. As previously mentioned, treatments that show efficacy in individuals with the 
APOE4 allele are much sought after, with a number of otherwise promising therapeutic approaches 
showing either no efficacy or increased side effects in this genotype [60,62,346-348]. However, it should 
be noted that the inverse has also been found, with APOE4 carriers showing either a greater response to 
treatment than the other APOE carriers or no significant difference [349-351]. Regardless, inhibition of 
MMP9 would likely be beneficial in all APOE genotypes as a result of the multiple AD pathologies in 
which MMP9 is implicated, including the shedding of LRP1 at the BBB as outlined in this thesis.
We also identified an increased expression of MMP9 in cerebrovascular cells as a result of AP exposure. 
This is of particular interest, as accumulation of AP in AD may result in a self-perpetuating increase in 
MMP9 expression and release, leading to more LRP1 shedding and therefore less clearance of Ap
apoE2>apoE3>apoE4
Soluble
LRP1
MM P9 ADAMIO
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Shedding prevents 
transcytosis and clearance 
of APEEA1Endothelial 
cells (BBB) V  apoE2>apoE3>apoE4ra b ll
Blood
Figure 6.1 Proposed mechanism for the involvement of apoE in the regulation of Ap clearance through 
the BBB. The shedding of LRP1 at the cell surface results in the formation of a soluble LRP1 fragment 
which is no longer able to transcytose Ap. Two of the proteases responsible for this shedding are 
ADAMIO and MMP9, the latter of which was found to be apoE dependent (apoE2<apoE3<apoE4) and 
had expression which was inducible by Ap. Once AP binds to LRP1, it is internalised and transported 
through the early endosomal compartments (EEA1) to the recycling compartments (ra b ll) where it is 
subsequently released into the plasma. Clearance of AP through the BBB occurs in an apoE isoform 
specific manner (apoE2>apoE3>apoE4). The presence of apoE3 or apoE4 results in an accumulation of 
AP in early endosomes resulting in an increase in the number and a swollen morphology of these 
endosomes.
through the BBB. This circular process could feasibly exacerbate the MMP9 mediated pathology at the
BBB, leading to  increased brain AP accumulation and MMP9 mediated pathology. The ability to  break
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this cycle through the inhibition of MMP9 could have an enormous impact on the progression of AD. 
However, the use of MMP9 inhibitors as a therapeutic strategy has previously been hampered by the 
high incidence of side effects of broad spectrum MMP inhibitors such as musculoskeletal pain and 
inflammation [326-328]. Fortunately, more recent studies that selectively targeted MMP9 appear to 
circumvent the side effects associated with broad spectrum MMP inhibition while retaining the efficacy, 
suggesting that selective inhibition of MMP9 remains a viable therapeutic strategy [329,330].
6.3 Conclusions
Despite the increasing prevalence of AD and a growing elderly population, there is a lack of disease 
modifying therapies with all currently approved therapies being directed towards palliative care. In 
addition, the current therapies have only shown limited efficacy and are often only marginally effective 
in a subset of AD patients [13-15]. While the magnitude and scale of the problem has now been 
recognised, with the World Health Organisation declaring the treatment of dementias a public health 
priority in 2012, there remains an urgent need to diversify the therapeutic avenues being investigated 
for the treatment of AD. This study focuses on a novel approach to facilitate the clearance of A3 from 
the brain through the BBB. In addition, we also investigated whether the well associated risk factor for 
AD, the APOE4 allele, has any mechanistic involvement in the LRP1 mediated clearance of A3 at the BBB.
We identified several mechanisms that were influenced by the apoE isoform, such as altered endosomal 
trafficking of A3 in the early endosomes as well as an apoE dependent mechanism that resulted in the 
ectodomain shedding of LRPl(Figure 6.1). We believe that inhibition of LRP1 shedding presents itself as 
an attractive and effective means of increasing the clearance of A3 across the BBB by increasing the 
functional the full length LRP1 population. Of the proteases investigated in this study, MMP9 proved to 
be the most promising target for therapeutic intervention, primarily as a result of its strong association 
with several AD pathologies. In addition, MMP9 activity was found to be mediated in an apoE isoform
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dependent manner. This novel association could prove particularly beneficial to individuals with the 
APOE4 allele who are most at risk of developing AD.
To our knowledge, this is the first demonstration that the proteases responsible for the ectodomain 
shedding of LRP1 can be successfully modulated to facilitate the clearance of A3 through the BBB. This 
approach represents a novel therapeutic avenue for the treatment of AD that may be invaluable for 
reducing the accumulation of A3 in the brain. In addition, there has never been a therapeutic approach 
that is specifically targeted toward restoring the BBB clearance of A3- This strategy may open up a new 
category of viable therapeutics that specifically targets dysfunctional BBB clearance. We believe that 
following this line of enquiry may be of the upmost importance if a successful therapy for AD is to be 
developed.
6.4 Future directions
The findings from this thesis support the targeting of the proteases involved in the shedding of LRP1. In 
particular, the inhibition of MMP9 may prove to be a particularly desirable therapeutic avenue as a 
result of the multiple AD pathologies in which it is involved. To our knowledge, there have currently 
been no studies investigating the impact of MMP9 inhibition in an AD mouse model. Therefore, future 
studies will investigate whether treatment with the MMP9 selective inhibitor SB-3CT is able to alter the 
AD phenotype in a mouse model of AD by increasing the BBB clearance of A3- In addition, assessment of 
MMP9 expression in the vasculature of non-demented and AD individuals stratified by APOE genotype 
may prove to be particularly interesting as it may reveal APOE dependent expression patterns. Findings 
from these studies may give additional rationale for the increased risk of developing AD that the APOE4 
allele confers.
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Figure 9.1 (A) Release of Lactate Dehydrogenase by HBMECs after A042 treatment. HBMECs were 
incubated with AP42 for 48hours before the media was collected and tested for the presence of the 
well known cytoxic marker, LDH (Roche Diagnostics, Germany) according to the manufacturer's 
instructions. At concentrations higher than lpM  A(342, a significant increase in the levels of LDH was 
detected. The largest increase was witnessed in the tPA positive control (lOnM) which had 
significantly higher levels of LDH compared to all other treatments. No significant difference was 
detected between control and Ap42 at any concentration. (B) Shedding of LRP1 in HBMECs after 
treatment with Ap42 (10pM) and tPA (lOnM). Treatment with AP42 significantly increased the levels 
of soluble LRP1 with exposure of HBMECs to tPA resulting in a small increase that did not reach 
statistical significance. Values represent mean ± SEM (n = 3) and are expressed as % change LDH from 
control. Statistical significance by assessed by one-way ANOVA followed by Tukey's post hoc analysis. 
*p<0.05 compared to OpM AP42, #p<0.0001 compared to all other treatments.
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Group ID Sex Age APOE
PMI
(hours) Clinical Summary
Plaque
total
Braak
Score Cerad NP Source
AD 001 F 76 4/4 3 AD 13.75 IV pAD BSHR
AD 002 F 96 3/3 2.75 AD 12.5 V pAD BSHR
AD 03 F 77 4/4 4 AD 13.25 V definite AD BSHR
AD 004 M 86 3/3 3 AD, PD 14.25 V pAD BSHR
AD 005 F 87 3/3 3 AD 13.5 V definite AD BSHR
AD 006 F 84 3/3 1.83 pAD 14.5 VI definite AD BSHR
AD 007 M 86 3/3 2.16 pAD 14.5 IV definite AD BSHR
AD 008 M 76 4/4 4 AD or PiD 11.75 V definite AD BSHR
AD 009 F 85 3/3 1.5 pAD 14 VI definite AD BSHR
Control 010 F 83 2/2 4.83 Control, D, action T 10 II possible AD BSHR
AD 011 F 96 3/3 3 Possible AD 13.75 IV pAD BSHR
Control 012 M 91 3/3 1.5 Control 0 II not AD BSHR
AD 013 F 86 3/3 2.5 AD 15 V definite AD BSHR
Control 014 M 82 3/3 3 Control, mPD, S 4 III not AD BSHR
AD 015 F 75 3/3 2.83 CD 15 V definite AD BSHR
Control 016 M 85 3/3 3.5 Control, pMCI 0 1 not AD BSHR
Control 017 M 92 3/3 3 ND control, T 8 III possible AD BSHR
AD 018 F 92 4/4 2.83 AD 14.5 VI definite AD BSHR
Control 019 M 89 3/3 5.5 Normal control 0 II not AD BSHR
AD 020 F 82 3/3 4 AD 15 VI definite AD BSHR
AD 021 M 72 4/4 3 AD 15 V definite AD BSHR
Control 022 M 81 3/3 2.25 ND control, T 0 III not AD BSHR
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Control 023 M 80 3/3 2.5 ND control 0 III not AD BSHR
Control 024 M 38 3/3 3 ND control 0 0 not AD BSHR
Control 025 M 80 2/2 3.5 ND control, PC 4.5 III not AD BSHR
AD 026 F 88 4/4 2.28 AD, PD, NOS 13 VI definite AD BSHR
Control 027 M 38 2/2 9 Control NA NA NA M
AD 028 M 83 4/4 3 AD 10 V definite AD BSHR
Control 029 F 91 2/2 4 ND control 11 IV possible AD BSHR
Control 030 M 49 4/4 10 ND control NA NA NA M
Control 031 F 33 3/3 20 ND control NA NA NA M
Control 032 M 32 4/4 13 ND control NA NA NA M
Control 033 F 34 4/4 12 ND control NA NA NA M
Control 034 F 60 4/4 18 ND control NA NA NA M
Control 035 M 58 4/4 17 ND control NA NA NA M
Control 036 M 49 4/4 5 ND control NA NA NA M
Control 037 M 51 4/4 25 ND control NA NA NA M
Control 038 F 54 2/2 11 ND control NA NA NA M
Control 039 F 102 2/2 1.67 ND control 0 II not AD BSHR
Control 040 M 78 2/2 1.66 ND control 9.75 1 not AD BSHR
AD 041 M 68 4/4 2 AD 15 VI definite AD BSHR
Control 042 F 81 4/4 3 Control 7.5 II not AD BSHR
AD 043 F 93 4/4 2.5 pAD 14 VI definite AD BSHR
Control 044 F 70 4/4 2 Control 8.25 1 not AD BSHR
AD 045 M 83 4/4 2.83 AD 15 VI definite AD BSHR
Control 046 F 76 3/3 2.75 Control 4.6 1 possible AD BSHR
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Control 047 M 84 3/3 2.5 ND Control 9.25 III possible AD BSHR
Control 048 F 91 2/2 2.5 Control; pMCI 1 III not AD BSHR
AD 049 F 73 2/2 7.3 AD 6.1 NA NA MtS
AD 050 F 107 2/2 15.1 AD 4.96 NA NA MtS
Control 051 F 80 2/2 3.8 ND Control 0 NA NA MtS
Control 052 F 94 2/2 2.1 ND Control 0 NA NA MtS
Table 9.1 Demographics for human inferior frontal gyrus samples. MI=post mortem interval, ND= Non-demented, 
PAD=Alzheimer's disease, pAD=probable AD, PD=Parkinson's disease, mPD=mild Parkinson's disease, PiD=Pick's disease, 
MCI=mild cognitive impairment, pMCI= possible mild cognitive impairment, T=tremor, S=Stroke, PC=pancreatic cancer, 
CD=corticobasal degeneration, BSHR=Banner Sun Health Research Institute, M=University of Maryland, MtS=Mount Sinai 
Hospital, NA=not available
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